header logo image


Page 749«..1020..748749750751..760770..»

GSK, Pfizer contradict on the future of consumer health JV report – Endpoints News

January 20th, 2020 5:49 am

SAN FRANCISCO Few CEOs tell a story better than bluebirds Nick Leschly.

He cuts a Jeff Bezos figure on stage at the Colonial Room, the JP Morgan presentation hall for A-list biotechs: lean and bald, fast-talking and vest-wearing. He explains in simple language, apologizing when he has to brush on the data. It helps that he has a good story to tell.

We treated them one time, Leschly tells a packed crowd, gesturing to the slide behind him. Look what happened.

The slide shows 9 horizontal bars studded with diamonds. Each bar, he explained, represented a sickle cell patient, and each diamond represented a severe medical event, such as a pain crisis. The diamonds stud one side before the therapy and vanish on the other, afterward.

A 99% reduction in these events this is a functional cure for sickle cell disease, Leschly says. This is unprecedented data.

Upstairs and an hour later, Ted Love stands before a narrow conference room in his suit and polka-dot tie. Love, the CEO of Global Blood Therapeutics, is a 60-year-old physician. His voice trails off at the end of sentences, and the story he tells is less compelling. There are no cured patients.

This is the first drug that addresses the root cause of sickle cell disease, Love says, speaking in front of a slide showing a white pill bottle for GBTs new drug Oxbryta. Right in the label, it says that this drug inhibits polymerization.

In the 60 years after scientists discovered the cause of sickle cell, almost no treatments emerged, even as the condition debilitated hundreds of thousands of Americans, most of them black or Hispanic. But the last few years have seen a resurgence of interest as new technologies have made the disease seem newly beatable.

Unlock this story instantly and join 70,000+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

See the original post here:
GSK, Pfizer contradict on the future of consumer health JV report - Endpoints News

Read More...

Ten Years of Unraveling the Genomics of Parkinson’s Disease – Technology Networks

January 20th, 2020 5:48 am

The International Parkinson Disease Genomics Consortium (IPDGC) has now been in existence for ten years. In an open accessarticlepublished in theJournal of Parkinson's Diseasethe consortium reviews the progress made over the past decade in the genomics of Parkinson's disease (PD) and related disorders including Lewy body diseases, progressive supranuclear palsy, and multiple system atrophy and looks ahead at its future direction and research priorities.

Since PD was first defined, it has been suspected that there was a genetic component. In June 2009, a small group of investigators met to discuss a potential research alliance focused on the genetics of PD. The outcome was the creation of the IPDGC, a group focused on collaborative genetics research, enabled by trust, sharing, and as little paperwork as possible. This article summarizes the efforts of the IPDGC to date and places these in the context of a decade of progress in PD genomics. It also discusses the future direction of IPDGC and its stated research priorities for the next decade.

The IPDGC was born out of a realization that no single investigator could deliver on the promise of modern human genetics in isolation, explained lead author Andrew Singleton, PhD, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA. We realized that to truly leverage the incredible gains in genetic technologies in the PD space, at scale, would require a highly collaborative approach. This notion brought a small group of PD geneticists together with the common goal of building an effective, transparent, and functional collaboration.

Since its inception, the IPDGC has grown considerably, now including more than 100 scientists from around the world with meetings at least once a year. The focus has also expanded to include clinical and functional investigation of PD at scale. Most recently, the IPDGC initiated major research efforts in East Asia and Africa and has prioritized collaborations with ongoing major efforts in India and South America.

The coordinated analysis of genome-wide association (GWA) data was perhaps the first success for IPDGC and has continued to be a mainstay of our work, noted Dr. Singleton. This work has centered on available genome-wide SNP genotyping of IPDGC members case and control cohorts from the USA, Canada, England, Wales, The Netherlands, France, Germany, Italy, Spain, Austria, Finland, Norway, Estonia, and Australia. These studies have involved collaboration within IPDGC and with groups from industry, including Genentech and 23andMe. The source diversity and size of these sample series have grown considerably, from the first efforts that centered on around 1,500 cases and a similar number of controls, to the most recent effort that included dense genotyping in more than 50,000 cases and proxy-cases, and around 1.4 million controls. As in other disorders, as sample size has grown, so has power and the number of loci detected. Currently, there are about 90 known risk variants for PD.

Collaboration among IPDGC members has furthered knowledge, including:

Future challenges the consortium has identified include expanding the known genetic architecture; genetics in diverse ancestries; advanced cohort building; and creating PD resources for the research community.

The importance of the dissection of genetic risk in non-European ancestry populations has led the consortium to invest more in establishing research in underrepresented groups. With the support of the Michael J. Fox Foundation for Parkinsons Research, the IPDGC has initiated largescale efforts in South East Asia and China and across Africa. It is also working closely with collections centered in India, LUX-GIANT, and LARGE-PD.

The field of PD genetics is one that has changed dramatically over the last ten years, commented Dr. Singleton. There has been an exponential growth in our appreciation of the genetic architecture of the disease and a greater understanding of how to proceed with genetic prosecution of PD.

Our future path promises to expand this work and leverage its clinical, mechanistic, and biological potential. Thus, while we believe the work of the IPDGC has had a significant and lasting impact on our field over the last ten years, we are even more excited by the course we have charted for the next decade.

Reference:The International Parkinson Disease Genomics Consortium (IPDGC). (2020).Ten Years of the International Parkinson Disease Genomics Consortium: Progress and Next Steps. The Journal of Parkinson's Disease.DOI: 10.3233/JPD-191854.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See original here:
Ten Years of Unraveling the Genomics of Parkinson's Disease - Technology Networks

Read More...

Cobb-Vantress appoints genetics executive – The Poultry Site

January 20th, 2020 5:48 am

Today, Cobb-Vantress appointed Dr Mark Cooper as managing director of genetics to oversee the companys global genetic program. Effective immediately, Dr Cooper will continue work to achieve genetic gains and competitive advantage through alignment of Cobbs breeding program with its product strategy, developing a portfolio of products to meet growing global market needs. He will report to Dr Aldo Rossi, vice president of research and development (R&D).

In his new role, Dr Cooper will lead a global, multifunctional team, including Dr Rachel Hawken, senior director of genetics; Dr Manouchehr Katanbaf, senior geneticist; and Dr Sriram Krishna, senior geneticist. Prior to this appointment, Dr Cooper previously worked as director of product testing. Since joining Cobb, he has also served as pedigree geneticist responsible for male line development, European director of genetics, director of genetics for all of Cobbs breeding programs, and director of product management.

Cobb has been dedicated to genetic research and the responsible use of technology for over 100 years, said Dr Rossi. Dr Cooper has made a big impact in his nearly 20 years with Cobb, and were looking forward to the continued advancements we expect him to accomplish in this new position.

In his time at Cobb, Dr Coopers research has focused on technology development and implementation in the breeding program, welfare parameters and meat quality. He has also spent time with global business leaders and customers to understand and update the R&D team on the product portfolio needed for the future. Most recently, he led Cobbs product testing team, helping to evaluate the companys product performance and development.

Im honored to take on the position of managing director of genetics, said Dr Cooper. Im fortunate because Cobb invests a significant percentage revenue into research and development, allowing us to continue leading the way in genetic progress.

Dr Cooper earned a bachelors degree in poultry science from Texas A&M University, a masters degree in poultry genetics from the University of Georgia, and a PhD in poultry genetics from the University of Arkansas.

See more here:
Cobb-Vantress appoints genetics executive - The Poultry Site

Read More...

Study Yields Insight Into Genetic Architecture of Anxiety – Psych Congress Network

January 20th, 2020 5:48 am

A genome-wide association study has identified several human genome regions related to anxiety risk. Researchers published their findings online in The American Journal of Psychiatry.

The findings are an important step forward in understanding anxiety disorders and the contribution of genes, said lead author Daniel F. Levey, PhD, of Yale University in New Haven, Connecticut, and the Veterans Affairs Connecticut Healthcare Center.

Dr. Levey and colleagues tapped data from the VA Million Veteran Program, a biobank that includes genetic, environmental, and medical information, to compare the genomes of almost 200,000 people.

The study identified 5 locations on the human genome associated with anxiety in Americans of European descent and 1 location in African Americans. Gene variants at the locations, researchers explained, could increase the risk for anxiety.h

Scans Show Shared Brain Abnormalities With Mood, Anxiety Disorders

The strongest locations were near genes involved with global regulation of gene expression (SATB1) and the estrogen receptor alpha (ESR1), according to the study. Another location (near MAD1L1) was previously linked with bipolar disorder and schizophrenia risk.

The study provides the first significant genome-wide findings regarding anxiety in people of African ancestry, Dr. Levey noted.

Minorities are underrepresented in genetic studies, and the diversity of the Million Veteran Program was essential for this part of the project, he said. The genetic variant we identified occurs only in individuals of African ancestry and would have been completely missed in less diverse cohorts.

Some 18% of participants in the Million Veteran Program are African American.

Jolynn Tumolo

References

Levey DF, Gelernter J, Polimanti R, et al. Reproducible genetic risk loci for anxiety: results from 200,000 participants in the Million Veteran Program. The American Journal of Psychiatry. 2020 January 7;[Epub ahead of print].

Million Veteran Program study sheds light on genetic basis of anxiety [press release]. Baltimore, Maryland: Veterans Affairs (VA) Research Communications; January 7, 2020.

Read more here:
Study Yields Insight Into Genetic Architecture of Anxiety - Psych Congress Network

Read More...

Florida Genetic Information Bill Advances in House – Government Technology

January 20th, 2020 5:48 am

(TNS) Incoming House Speaker Chris Sprowls had little trouble Thursday convincing members of a House health-care panel to approve legislation that would prohibit life-insurance, long-term care insurance and disability-insurance companies from using customers genetic information in changing, denying or canceling policies.

Florida would become the first state to have such a law if Sprowls proposal is ultimately passed by the Legislature and signed by Gov. Ron DeSantis.

Members of the House Health & Human Services Committee passed Sprowls bill (HB 1189) without any debate, and committee Chairman Ray Rodrigues, R-Estero, praised Sprowls for introducing the bill.

I think our privacy is important. And I think its equally important to be a visionary, to look forward and I 'm happy that Florida is going to be the state that leads the way on this issue, Rodrigues said.

Insurance industry lobbyists, who opposed the measure, sat quietly, agreeing to waive their speaking time.

Curt Leonard, regional vice president for state relations for the American Council of Life Insurers, said his association had expressed concerns on the issue for the past two years.

Weve expressed our concerns with Speaker Sprowls and other interested parties on this issue going back to 2018. So theres no point in repeating the same things over and over again, in the interest of the committee's time, Leonard said. That being said, we do share the speaker-designates (Sprowls) concerns about privacy. I think it's a concern for everybody.

The bill will have to clear the Commerce Committee before it would be ready to go to the full House. Sprowls, R-Palm Harbor, is slated to become speaker after the November elections.

In addition to preventing insurers from using the information in making policy decisions, Sprowls bill also would block the companies from requiring or soliciting genetic information from applicants.

Sprowls said insurance companies have for years been able to sell policies without having access to the genetic data.

Insurance carriers have been successful without access to genetic information. They have been able to provide affordable coverage to consumers without genetic information. Insurance is about spreading risk, not guaranteeing the outcomes or rewards to the (carriers). And affordable life, disability, and health insurance should not be available simply to the genetic elite, Sprowls said.

While Sprowls influence looms large in the House, he must convince the Florida Senate to go along. For that, Sprowls said he will look to Sen. Kelli Stargel, R-Lakeland, to spearhead the issue.

Senate President Bill Galvano, though, told The News Service of Florida that he supports a potential compromise on the issue.

Leonard said a compromise would authorize consumers to use their private information any way they want to. And that might include them wanting to share their genetic science or genetic testing information, he said. So we dont like the idea that consumers will be handcuffed in how they use that information.

2020 The Orlando Sentinel (Orlando, Fla.) Distributed by Tribune Content Agency, LLC.

Link:
Florida Genetic Information Bill Advances in House - Government Technology

Read More...

Functional validity, role, and implications of heavy alcohol consumption genetic loci – Science Advances

January 20th, 2020 5:48 am

Abstract

High alcohol consumption is a risk factor for morbidity and mortality, yet few genetic loci have been robustly associated with alcohol intake. Here, we use U.K. Biobank (n = 125,249) and GERA (n = 47,967) datasets to determine genetic factors associated with extreme population-level alcohol consumption and examine the functional validity of outcomes using model organisms and in silico techniques. We identified six loci attaining genome-wide significant association with alcohol consumption after meta-analysis and meeting our criteria for replication: ADH1B (lead SNP: rs1229984), KLB (rs13130794), BTF3P13 (rs144198753), GCKR (rs1260326), SLC39A8 (rs13107325), and DRD2 (rs11214609). A conserved role in phenotypic responses to alcohol was observed for all genetic targets available for investigation (ADH1B, GCKR, SLC39A8, and KLB) in Caenorhabditis elegans. Evidence of causal links to lung cancer, and shared genetic architecture with gout and hypertension was also found. These findings offer insight into genes, pathways, and relationships for disease risk associated with high alcohol consumption.

Alcohol consumption is associated with over 60 diseases, with the risk of these comorbidities generally increasing with greater exposure (1). Excessive consumption of alcohol is considered a result of complex interactions between genetic and nongenetic risk factors. Nongenetic factors associated with levels of alcohol intake include gender (2), age at first alcohol use (3), duration of poverty and involuntary unemployment (4), and other lifestyle risk factors (5).

Meta-analysis from twin and adoption studies has shown that half of the variance for alcohol use disorder (AUD) is explained by genetic factors (6). The discovery of well-replicated risk loci, however, has been limited to the alcohol metabolizing genes alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH). Missense variants, rs1229984 (G-->A; p.Arg48His) in ADH1B and rs671 (G-->A; p.Glu504Lys) in ALDH2, are protective against higher alcohol consumption and alcohol misuse phenotypes (7). For example, in a meta-analysis of ~3800 European ancestry individuals, the ADH1B rs1229984 variant was strongly associated with reduced risk of alcohol dependence and lower number of maximum drinks in 24 hours (8). The ADH1B and other ADH and ALDH variants that are associated with alcohol consumption occur at low frequency among European ancestry populations but are more common in East Asian ancestry populations, where the standardized population prevalence of alcohol misuse is lower (9).

Larger samples and genome-wide screens have been used to identify previously unidentified loci beyond the ADH-ADLH cluster. Alcohol consumption phenotypes are of specific interest to the field as they are often more applicable to the wider population than the AUD criteria. Through genome-wide association studies (GWAS), single-nucleotide polymorphisms (SNPs) mapping to/near KLB, AUTS2, SERPINC1, ANKRD36, GCKR, PXDN, CADM2, HGFAC, SLC39A8, and TNFRSF11A have been associated with alcohol consumption in European ancestry populations at genome-wide significance (P < 5 108) (1015). However, apart from association signals at KLB and GCKR, strong evidence of replication has been limited.

In this study, our aim was to determine factors associated with heavy alcohol consumption in white British individuals from the U.K. Biobank (UKB) (www.ukbiobank.ac.uk/), alongside exploring the functional relevance of genome-wide significant variants using model organisms and data mining techniques.

The application of the phenotype definition resulted in the identification of 21,967 cases and 103,282 controls that had complete data for all covariates. The covariates included in the final logistic regression model and carried forward to the GWAS analysis were (table S1) age at recruitment, sex, smoking status (anytime versus never), property ownership (own versus rent), body mass index (BMI), Townsend deprivation index at recruitment, adopted as a child, and long-standing illness, disability, or infirmity (yes or no).

We tested for SNP-level association with our high alcohol consumption phenotype in UKB. A total of 11,141,077 SNPs survived central quality control (QC) by UKB and post-GWAS filtering for imputation quality and minor allele frequency. The GWAS data test statistics showed modest deviation from the null (GC = 1.09; Fig. 1, inset), although linkage disequilibrium (LD) score regression intercept = 1.02 suggests most of the inflation is consistent with polygenic architecture. We then carried forward lead SNPs at P < 5 106 from UKB to Genetic Epidemiology Research in Adult Health and Aging (GERA) for replication. We report validated associations that meet genome-wide significance in the meta-analysis of UKB and GERA, which also demonstrate nominal association with the same direction of effect in GERA (Table 1). A summary of all SNPs reaching P < 5 108 in UKB can be found in table S2. We identified six loci attaining genome-wide significant association with alcohol consumption after meta-analysis and meeting our criteria for replication: ADH1B (rs1229984; P_meta = 2.3 1066); KLB (rs13130794; P_meta = 5.7 1016); BTF3P13 (rs144198753; P_meta = 4.1 1029); GCKR (rs1260326; P_meta = 1.5 1013); SLC39A8 (rs13107325; P_meta = 6.7 109); and DRD2 (rs11214609; P_meta = 4.3 109) (Table 1).

Inset: QQ plot of expected versus observed GWAS results from UKB, demonstrating modest deviation from the null, GC = 1.09.

OR, odds ratio; CI, confidence interval.

Multiple distinct signals of association observed at alcohol consumption loci. Conditional analyses revealed an additional signal (P < 1 105) (Table 2) at the SLC39A8 locus (NFKB1). Given ADH1B and BTF3P13 are located <1 Mb apart on q23 of chromosome 4, we conducted a wider conditional analysis across a 1.5-Mb region, which included both SNPs. The analysis identified eight independent SNPs mapping to/near ADH1A, ADH1B, ADH4, ADH5, TSPAN5, and EIF4E. The signal mapping to BTF3P13 did not meet locus-wide significance in conditional analysis, suggesting a false positive for this variant.

Joint models refer to the estimated joint effects of all selected SNPs in a region (i.e., all independent SNPs are fitted together).

Previously reported loci. The signals described in this section meet our validated association criteria and have been reported for various alcohol phenotypes by other groups. The lead SNP at ADH1B, rs1229984 [risk allele frequency (RAF), 0.980; P = 3.3 1036; fig. S1A], is the missense variant (G-->A; p.His48Arg) that has been widely replicated. The lead SNP rs13130794 (RAF, 0.632; P = 4.0 109; fig. S1B) is located in the KLB locus and has been reported to be associated with alcohol intake in the UKB (11) and a separate European cohort of >98,000 individuals (10). The lead variant in chromosome 2, rs1260326 (RAF, 0.612; P = 2.6 108; fig. S1C), is in GCKR, a glucokinase regulatory gene. This specific SNP has been reported as genome-wide significant for alcohol consumption (i.e., drinks/week) in large-scale European ancestry (11, 13) and transethnic populations (15). The lead SNP rs13107325 (RAF, 0.928; P = 1.6 108; fig. S1D) is in the zinc transporter gene, SLC39A8, which has been linked in Europeans to AUD Identification Test (AUDIT) (14) and AUDIT-C outcomes, and to AUD diagnosis (15). Last, rs11214609 (RAF, 0.395; P = 4.3 109; fig. S1E) was the SNP in the DRD2 locus. DRD2 often has been cited in addiction phenotypes and has been identified for AUD, but not alcohol consumption (15).

Nonreplicated signals reported elsewhere. We also observed genome-wide significant evidence of association in UKB at FTO and CRHR1, but these signals could not be validated in GERA. There is, however, evidence for association with alcohol-related phenotypes at these loci from other studies. The lead SNP rs55872725 (RAF, 0.599; P = 2.6 108) is in the FTO gene. This locus has recently been reported to be associated with AUDIT-C and AUD diagnosis in European ancestry individuals (15). Different index variants were reported between studies, rs62033408 for AUDIT-C and AUD diagnosis outcomes, but the SNPs are in strong LD with each other (r2 = 0.92). The FTO locus has been strongly associated with BMI, obesity, and, subsequently, type 2 diabetes as a clinical end point. Our lead SNP in this locus is in complete LD (r2 = 1.0) with rs1558902 in Europeans, which is the lead SNP for BMI in the largest published GWAS to date (16). The CRHR1 locus, with rs1635291 (RAF, 0.754; P = 4.5 1010) as the lead SNP, has been identified through gene-based analysis in a previous alcohol consumption GWAS where never drinkers were excluded. However, no other groups have reported this locus directly through GWAS. Given the previous associations for these loci with covariates included in our analysis but not in the GERA dataset, we explored the potential for collider bias at rs55872725 when not adjusting for BMI, and rs1635291 when not adjusting for smoking; the results were consistent at 6.5 106 and 2.8 108, respectively. We also found our lead SNP in the CRHR1 locus to be in strong LD (r2 = 0.87) with a tag SNP rs1800547 for a common inversion polymorphism in 17q21.31 (17).

Of the six validated variants from the UKB and GERA cohorts, three were identified as expression quantitative trait loci (eQTLs) through the Genotype-Tissue Expression (GTEx) database (table S3). rs11214609 showed evidence of being an eQTL in various tissues for nearby genes, ANNK1 and TTC12. rs13130794 was associated with the expression of RFC1 in the cerebellar hemisphere and skeletal muscle and UDGH in blood. rs1260326 was a broader eQTL with evidence across eight loci and various tissues including skeletal muscle, thyroid, and adrenal glands. Table S4 describes the LD between the top eQTL SNP for any eQTL signal and the GWAS SNP. None of the SNP pairs demonstrated evidence of colocalization based on a threshold of LD r2 > 0.8.

The validated SNPs were submitted to Gene ATLAS to explore phenome-wide association study (PheWAS) outcomes in disease phenotypes via International Statistical Classification of Diseases, 10th Revision (ICD-10) codes. Evidence suggests that these SNPs contribute to a range of diseases including alcohol dependence, hypertension, skeletal disorders, gout, alcoholic liver disease, ischemic heart diseases, metabolic disorder, obesity, and diabetes mellitus (table S5). The ADH1B variant is associated with lipid metabolism disorder, giving further link between alcohol intake and liver fat accumulation.

A set of 37 loci, which reached 5 106 with heavy drinker status phenotype in UKB, were submitted to the Reactome Knowledgebase for pathway analysis (table S6). Six pathways across three distinct processes were found to be significant. The most prominent outcome related to signaling of phosphatidylinositol 3-kinase (PI3K) and PI3K/AKT pathways, particularly in reference to cancer. Dysfunction of the PI3K/AKT pathway is widely implicated in many cancers and is a key regulator of cell survival through downstream targets (18). The genes implicated in these pathways were KLB and ESR1 (fig. S2). The other two pathways were neurexins and neuroligins, driven by LRRTM4 and NRXN3, and TFAP2 (AP-2) family regulation of transcription of growth factors and their receptors, driven by ESR1.

Through genetic correlation analysis of the entire genome, we identified 21 significant correlations that survived multiple testing correction. These outcomes are summarized in Fig. 2. The traits with the strongest correlations included smoking variables [e.g., ever versus never smoked (rg = 0.48, PFDR = 2.60 1013) and age of smoking initiation (rg = 0.41, PFDR = 0.006)], several lung cancer outcomes [e.g., squamous cell lung cancer (rg = 0.37, PFDR = 0.006) and lung cancer (rg = 0.36, PFDR = 1.20 104)], and mothers age at death (rg = 0.41, PFDR = 1.60 104). Several education measures and mental health conditions were also found to have significant correlations.

Mendelian randomization (MR) was used to examine the causal relationship between our heavy drinker case-control phenotype and 111 selected traits and clinical outcomes. The number of SNPs used for instrumental variables for each outcome test varied between two and six. Twelve outcomes including four insulin-related and two lung cancer outcomes demonstrated nominal significance using the inverse varianceweighted (IVW) method, although only evidence of a protective effect for ischemic stroke survived multiple testing correction (table S7). The MR-Egger regression intercept demonstrated no evidence of horizontal pleiotropy for the 12 outcomes (P 0.11). Single SNP analysis revealed that rs1229984 was not included in the instrumental variable for ischemic heart disease (SNP or appropriate proxy not available in the outcome dataset). Given rs1229984 demonstrates a consistent and large effect size across genetic studies of alcohol-related phenotypes, it is questionable whether the outcome can be considered as truly representative for this disease.

To further explore the potential causal effect of heavy alcohol consumption on lung cancer outcomes and allow for potential pleiotropy that might be driven by smoking, we repeated our GWAS analysis stratified for smoking status (ever versus never) and performed MR to assess potential collider bias. The SNPs used as the instrumental variable in the original analysis were retained, and lung adenocarcinoma and lung cancer were the only outcomes investigated. Evidence of consistent outcomes was observed in both stratified groups using IVW, although lung cancer in never smokers was the only outcome that did not reach the statistical significance threshold (P = 0.085).

To verify whether validated genetic targets (i.e., ADH1B, GCKR, SLC39A8, and KLB) had a conserved role in phenotypic responses to alcohol, we investigated the acute effects of ethanol on the nematode worm, Caenorhabditis elegans. In comparison to wild-type animals, those with a loss-of-function mutation in the worm ortholog for ADH (sodh-1 in C .elegans) had a statistically enhanced ethanol response (Fig. 3) as has been previously described in detail (19). The effect of intoxicating ethanol on coordinated locomotion was next quantified for loss-of-function mutations in C. elegans glucokinase (GK; hxk-1) and solute carrier family 39 member 8 (SLC39A8; zipt-15) (Fig. 3). Without an ortholog for GCKR in C. elegans, we instead analyzed its downstream effector protein glucokinase itself. Loss-of-function mutations in these genes significantly reduced the effect of ethanol for GK and SLC39A8 (Fig. 3), underlining a conserved role for these genes in whole-animal responses to alcohol. We also quantified single mutations in the C. elegans orthologs for the -Klotho protein (KLB; klo-1 and klo-2) and found that individual mutations did not alter the ethanol phenotype (fig. S3A). A compound mutation of both klo-1 and klo-2 (20), however, did have a significantly enhanced ethanol effect (Fig. 3).

C. elegans with loss-of-function mutations in worm orthologs to ADH (sodh-1), glucokinase (hxk-1), solute carrier family 39 member 8 (zipt-15), and -Klotho protein (klo-2;klo-1) were exposed to ethanol, and the resultant effect on locomotion rate was determined. Results are presented normalized to locomotion of untreated worms [basal locomotion rate: 99.03 1.47 (Bristol N2 controls), 103.13 3.66 (sodh-1), 87.37 1.91 (hxk-1), 31.43 2.97 (zipt-15), and 99.90 21.7 (klo-2;klo-1)]. *P < 0.05.

To validate the effects seen in individual mutant strains, we performed RNA interference (RNAi) experiments to knock down expression of the contraindicated genes. In comparison to control, RNAi knockdown of GK (hxk-1) and SLC39A8 (zipt-15) resulted in the same phenotypic effects as did the mutations (Fig. 4). In our RNAi experiments, knockdown of ADH (sodh-1) did not result in a significant decrease. Similar to the KLB mutations, individual knockdown of C. elegans KLB (klo-1 or klo-2) did not statistically enhance the ethanol phenotype and neither did knocking down both klo-1 and klo-2 simultaneously (Fig. 4). The lack of effect in the double knockdown is perhaps expected given that RNAi efficiency can be reduced with multiple targets (21). To validate the alcohol effect of KLB in C. elegans in an alternative method, we performed RNAi on individual KLB genes in the mutant strain of the other ortholog (i.e., klo-1 RNAi in the klo-2 background; klo-2 RNAi in the klo-1 background). In both cases, there were exceptionally enhanced effects of ethanol similar to that seen with the compound mutant strain (fig. S3B).

RNAi knockdown of worm orthologs to glucokinase (hxk-1) and solute carrier family 39 member 8 (zipt-15) phenocopies the loss-of-function mutations. Results are presented as locomotion of worms treated with ethanol normalized to untreated worms [basal locomotion rate: 87.63 21.6 (empty vector control), 94.17 2.91 (sodh-1), 77.60 2.34 (hxk-1), 60.0 2.34 (zipt-15), 90.97 3.56 (klo-1), 99.13 2.78 (klo-2), and 110.0 3.40 (klo-2;klo-1)]. *P < 0.05; n.s., not significant.

We report here a large alcohol consumption GWAS, including 125,249 white British participants, with subsequent replication and meta-analysis in an additional 47,967 individuals. Moreover, and as promoted by Salvatore and colleagues in this field (22), we conducted a post-GWAS study to investigate the biological implications of our findings. This includes providing evidence of a conserved role in phenotypic responses to alcohol for all targets available for investigation (ADH1B, GCKR, SLC39A8, and KLB) in C. elegans.

The primary strengths of this study are the (i) large sample size; (ii) replication and subsequent meta-analysis; (iii) post-GWAS analysis, including functional assessment using C. elegans; and (iv) use of a mixed-model approach in GWAS to account for relatedness. There are, however, several limitations that require discussion. First, the alcohol data and, therefore, the case-control phenotypes are based on self-reported alcohol intake. It is well documented that individuals underreport their alcohol consumption for a number of reasons. This presents risk of cases being mislabeled as controls, alongside the granularity of the data being reduced by the categorical approach. There are also differences in the measurement scale between discovery and replication cohorts. This difference was handled by applying a z score approach to meta-analysis. Second, we restricted analysis to those of white British ancestry to limit population structure variability on outcomes. This restricts generalizability outside of European populations. Third, we recognize limitations to our MR approach: (i) MR is considered most powerful when instrumental variables are from a continuous trait. This is of greater concern, however, when a disease-specific phenotype is used for instrument selection because of the likely contribution of various factors in disease pathology; and (ii) an inherent assumption of MR is that variants show no pleiotropy or direct effects on the outcome. This requires knowledge of the underlying biology under investigation, although this is rarely complete. Last, we were unable to undertake functional assessment of all genome-wide significant loci due to there being either no specific C. elegans orthologs, or too many nonspecific orthologs, or fatal consequences of gene knockdown.

The largest and most robust effects were observed in ADH1B, including replicated findings from the work in C. elegans for ADH (19), providing confidence for the selected phenotype. The biological validity of polymorphisms in ADH loci is well documented and discussed in detail in other GWAS publications (12).

KLB has been previously associated with alcohol phenotypes in European populations (10, 12). A biological basis for KLB has been proposed in mice, where those lacking -Klotho had increased alcohol consumption (10). This behavior was refractory to recombinant fibroblast growth factor 21 (FGF21), a hormone involved in sugar intake regulation and for which -Klotho is an obligate coreceptor. Hence, down-regulation of KLB may lead to sustained intake of alcohol and/or high-sugar food. Moreover, loss of both KLB isoforms in C. elegans caused an enhancement in the ethanol effects. Further evidence for energy processing pathways being implicated in alcohol consumption is demonstrated by the genome-wide significant outcomes for GCKR and SLC39A8, with these findings being consistent with recent publications (11, 13, 14). The data from our functional work in hexokinase and ZRT/IRT-like protein transporter supports the role of glucose metabolism pathways in the susceptibility to heavy alcohol consumption by demonstrating attenuation of the depressive effects of high-dose alcohol when hxk-1 and zipt-15 are independently knocked down. Although we failed to demonstrate replication between the UKB and GERA cohorts, potentially due to variation in phenotype, evidence from other GWAS showed consistent effects for FTO (23). The suggestive association with this pleiotropic locus adds further plausibility of common pathways implicated in the consumption of food and alcohol. The purported shared pathogenic architecture may result in dysregulation of brain reward pathways leading to excess consumption (24). Controlling for BMI within our GWAS suggests that the associations for alcohol consumption are independent of BMI, adding weight to the hypothesis of a potentially shared, rather than mediated, pathways.

DRD2 encodes the dopamine receptor 2 subtype and is linked to several neurobiological processes, including functional activation of reward circuits (25). Data from in vivo and in vitro experiments show DRD2 to be a susceptibility gene for alcohol dependence (26), and altering DRD2 expression leads to differential responses to substances and stimuli (27), conferring increased risk for addiction. Moreover, evidence suggests increased risk of relapse in alcohol and cocaine dependence, and heightened heroin, nicotine, and glucose craving when polymorphisms of DRD2 are present or there is low D2 receptor availability (28). The association of DRD2 with alcohol was confirmed in GWAS findings for AUD but not alcohol consumption, with authors proposing that the central nervous system is a fundamental element in the progression to clinical diagnosis (15). Our findings are somewhat contradictory given that participant categorization is based on U.K. alcohol units consumed per week, although the quantities for cases are often associated with high risk of AUD.

Together, the loci outside of the ADH/ALDH cluster suggest several common pathways associated with different types of compulsive behavior and addiction phenotypes. Considerable evidence from animal models and from humans supports convergence of these common etiologies in the brains limbic system regardless of the prior distinct mechanism of action and ultimate observable phenotype (29, 30). This suggests that addiction might be better considered as a pathobiological risk with different endotypes, rather than each specific phenotype (e.g., alcohol dependence, drug addiction, and gambling addiction) being independently characterized. From a therapeutics perspective, these outcomes provide additional and supportive evidence toward a number of targets that might be amendable to pharmacological intervention. Further investigation is required to determine which sites have the greatest potential. Data from the Open Targets resource (www.opentargets.org/) suggest that 49 drugs have reached phase IV investigation for DRD2 across a range of indications, including mental health disorders and cocaine dependence; no drugs are in development for ADH1B, KLB, GCKR, or SLC39A8. FGF21 has been explored due to links with KLB, but no drugs are in the market yet.

Using the GWAS outcomes from UKB enabled us to examine the relations between key variants/loci and traits and disease phenotypes. Genetic correlation analysis and MR consistently demonstrated an association with lung cancer. Determining alcohols contribution to lung cancer often has been limited by the strong positive correlation between alcohol intake and smoking. However, the outcomes from the MR provide potential evidence of a causal relationship in our overall sample and when stratified by smoking status. Alcohol is a known carcinogen and is implicated in cancers of the liver, colon, rectum, head and neck, and breast, for example (31), while evidence for lung is variable (32, 33). Lung cancer is a complex and multifactorial disease involving genetic and a range of measurable and nonmeasurable environmental and lifestyle factors. Hence, heavy alcohol consumption is one potentially modifiable risk factor to reduce disease incidence. An alternative hypothesis is through a joint risk locus in KLB that independently drives alcohol consumption and cancer risk. In addition to the above, -Klotho inhibits PI3K and, subsequently, AKT, an important pathway in normal cell function. The dysfunction of the PI3K/AKT pathway, identified in our pathway analysis, has been cited in cancerous cells and as a risk factor in cancer onset (18, 34). Down-regulation of KLB has been reported across several cancers (35, 36). However, some variations in findings exist (37), and no evidence is available in lung cancer. Basic cell line study would provide initial data on -Klotho expression in lung tumor cells.

Links to other diseases were also found. Drinking heavily was suggested as a protective factor for ischemic stroke. This is not consistent with traditional epidemiological findings or other MR findings using rs1229984 as the instrumental variable (38). However, the lack of rs1229984 in our instrumental variable for this analysis means the outcome should be interpreted with caution. The nominal evidence in several insulin measures suggests a wider biological association with glucose regulation, linking back to the potential importance of energy metabolism pathways in alcohol consumption. ADH1B and GCKR were associated with gout, and ADH1B alone with hypertension. The lead SNP at GCKR, rs1260326, has been shown to be a risk variant for gout in a separate GWAS (39), and rs1229984 in ADH1B has been identified for systolic blood pressure using a functional enrichment approach. Increasing alcohol consumption is a known risk factor for both gout and hypertension (40). Last, there was evidence for several skeletal complications with identified alcohol consumption variants. Alcohol intake represents a dose-dependent risk factor for fragility fractures due to the direct effects of alcohol on bone cell metabolism. Chronic alcohol consumption has been associated with a twofold increased risk of hip fracture in prospective cohort studies involving more than 16,000 subjects (41).

Our findings offer insight into genes, pathways, and causal relationships for disease risk associated with heavy alcohol consumption. The inclusion of model organism work to investigate the conserved role of loci alongside GWAS outcomes is novel in the alcohol field and adds validity for relevant outcomes. In addition, the correlation between the C. elegans phenotypic data with genome-wide association in humans reinforces a link between the acute physiological effect of alcohol and predisposition to excessive alcohol consumption. Specific findings suggesting joint reward/addiction pathways, the role of energy metabolism, casual links to lung cancer, and shared genetic architecture with gout and hypertension are of particular interest. Further investigation is required, however, to realize the potential of these outcomes and result in meaningful populationor clinical-level impact.

UKB is a large population cohort of ~502,000 individuals from the United Kingdom aged 40 to 69 years at the time of recruitment. Baseline assessment was undertaken at one of 22 centers across the United Kingdom between 2006 and 2010. Each participant completed a comprehensive demographic, lifestyle, and health questionnaire, underwent clinical phenotyping, provided biological samples (i.e., blood, urine, and saliva), and agreed to have his or her health record accessed for baseline and follow-up outcomes (42). Ethical approval for UKB was gained from the Research Ethics Service (REC reference: 16/NW/0274), and written informed consent was obtained from all participants. The current analyses were conducted under approved UKB data application number 15110.

Phenotype definition. Questions from the UKB baseline assessment were used to develop two study groups: heavy drinkers (cases) and drinkers not reaching criteria for cases (controls). All participants who indicated they consumed alcohol were asked to quantify their intake per week or per month using standard drink sizes [e.g., In an average WEEK, how many glasses of RED wine would you drink? (there are six glasses in an average bottle)]; pictures accompanied these questions to provide visual representation of each measure. We then applied a standardized number of U.K. alcohol units to each drink to enable an estimated number of units per week to be calculated (see the Supplementary Materials for more detail). Sex-specific heavy drinking was then defined as >35 U/week for women and >50 U/week for men. Any cases with values >4 SDs above the gender-specific means were removed. Controls were individuals who were not current abstainers from alcohol (i.e., 1 U/week) but did not reach the sex-specific criteria for heavy drinking and were drinking at similar levels to 10 years previous.

Genotyping, imputation, QC, and GWAS. In July 2017, UKB released genetic information (directly typed and imputed genotypes) for the entire cohort (n = 487,406) to approved collaborators. Most (90%) of the participants were genotyped on the UKB Axiom Array, with the remaining 10% genotyped on the Affymetrix UK BiLEVE Axiom Array. There is >95% content overlap between arrays. Genotyping, QC, and imputation were performed centrally by UKB and has been previously described (43). Imputation was performed up to combined reference panels from the 1000 Genomes Project (Phase 3), UK10K, and Haplotype Reference Consortium (44). Analyses were restricted to a subset of white British individuals, defined on the basis of self-reported ethnicity and genetic data.

Using UKB data, univariate and multivariate logistic regressions were used to determine covariates to be included in the GWAS analysis. Variables only available for the entire cohort and implicated in previous research were considered, and any values >4 SDs from the mean were removed (n = 7649 participants removed due to missing data). Variables reaching P < 0.01 in separate univariate analysis were carried forward to a multivariate model, where the stepAIC function of the MASS R package was used to determine stepwise entry of variables into the model. Collinearity was determined using variance inflation factor, and variables were accordingly removed from the final model (Variance Inflation Factor >10). An a priori decision was made to include age and sex in all models. Our rationale for using this approach is twofold: first, to account for confounding factors that may bias effect estimates, and second, to improve power by reducing residual variance.

Genetic association analysis in autosomes was conducted using a linear mixed model in BOLT-LMM v2.3.1 (45), adjusted for age at recruitment, sex, genotyping array, and nongenetic covariates identified in the logistic regression model. The BOLT-LMM model includes a random effect derived from a genetic relationship matrix to account for population structure and relatedness. Potential P value inflation due to residual population structure and relatedness was checked using genomic control following filtering of variants based on imputation quality (INFO 0.4) and minor allele frequency of 0.005. Distance-based clustering was used for defining loci, such that genome-wide significant SNPs were ranked from most significant to least significant, and SNPs were retained if they did not map 500 kb of a more significant SNP. Variants reaching P < 5 106 and surviving distance-based clustering (i.e., lead SNPs) in the UKB cohort were explored in the GERA cohort for the purposes of replication.

The GERA cohort was used for replication. GERA is part of the Kaiser Permanente Research Program on Genes, Environment, and Health (RPGEH) and has been described in detail elsewhere (46). In short, the cohort comprises 110,266 adult men and women who are consented participants in the RPGEH, an unselected cohort of adult participants who are members of Kaiser Permanente Northern California, an integrated health care delivery system. All study procedures were approved by the Institutional Review Board of the Kaiser Foundation Research Institute.

For this replication analysis, 47,967 GERA participants of non-Hispanic white ethnicity who had alcohol consumption information were included. Alcoholic drinks consumed per week as a quantitative trait (drinks/week) was assessed on the basis of the RPGEH survey as previously described (12) and as part of the Supplementary Materials. Genotyping using Affymetrix Axiom arrays (Affymetrix, Santa Clara, CA, USA) (47, 48), imputation using the cosmopolitan 1000 Genomes Project reference panel, and GWAS analysis were undertaken as detailed in the Supplementary Materials.

METAL was used to perform a fixed-effects meta-analysis between the UKB and GERA cohorts using Stouffers method to account for the effect sizes in discovery and replication being on different scales (49). An overall z-statistic and P value were calculated from a weighted sum of the individual statistics. Weights are proportional to the square root of the number of individuals examined in each sample and selected such that the squared weights sum to 1.0.

A validated association was defined as follows: (i) reaching P < 5 106 in the discovery cohort, (ii) demonstrating nominal association with the same direction of effect in the replication cohort, and (iii) meeting genome-wide significance in the meta-analysis of both datasets sets.

Conditional analysis was performed on validated associations using Genome-wide Complex Trait Analysis (50) (http://cnsgenomics.com/software/gcta/) and the GWAS outcomes from the UKB to identify independent signals in the same region as each lead SNP (500 kb); one model was fitted per region. A set of 5000 randomly selected UKB white British participants was used to develop a reference set to approximate LD. A threshold of P < 1 105 was used to select index SNPs for independent signals in each region, where the conditional estimates were derived from fitting all independent SNPs jointly (i.e., joint model).

Expression quantitative trait loci. The GTEx Portal (http://www.gtexportal.org) was used to assess whether the lead SNP at each locus was an eQTL for local genes across the range of available tissues (51). This approach uses gene expression information across various human tissue types and genotype data to build information on eQTLs using a 1-Mb cis-window around the transcription start site. All tissue types with more than 70 samples available within GTEx were evaluated in our analysis including the brain, heart, liver, skeletal muscle, and skin. Significant eQTLs were based on a false discovery rate (FDR < 0.05) correction. The LD between the top eQTL SNP for any eQTL signal and the GWAS SNP was assessed to explore whether the two signals colocalize with each other; an LD r2 > 0.8 in Europeans from the 1000 Genomes was considered evidence of colocalization.

Genetic correlations. LD Hub v1.9.0 (http://ldsc.broadinstitute.org/ldhub/) was used to identify genetic correlations through LD score regression between the binary alcohol phenotype and other complex traits (52). This method uses individual SNP allele effect sizes from GWAS summary statistics and the average LD in a region to estimate bivariate genetic correlations. We tested for genetic overlap between alcohol consumption from our GWAS and disease outcomes and related traits in European cohorts available in the LD Hub, except for UKB outcomes and metabolites due to the large number of potential comparisons. FDR < 0.05 was used to account for multiple comparisons.

Mendelian randomization. MR-Base v0.4.21 was used for performing two-sample MR to explore the causal relationship between alcohol consumption and other disease outcomes and related traits (53). Outcomes were selected from the NHGRI-EBI GWAS catalog and filtered for European ancestryonly populations. All genome-wide significant SNPs were initially considered. Before MR analysis, the identified SNPs were explored for independence using estimated LD scores from the 1000 Genomes Project European sample, where r2 0.001 among SNPs in a 10,000-kb region resulted in only the SNP with the lowest P value being retained. One hundred eleven outcomes were selected on the basis of being diseases of interest, metabolites influenced by alcohol and prominent in subsequent alcohol-related disease onset or progression (e.g., triglycerides), or other consequences of heavy alcohol consumption. Harmonization between exposure data and outcome data was undertaken to ensure effects corresponded to the same allele. Causal estimates between exposure and outcomes were obtained using the two-sample MR IVW method with FDR for multiple comparisons. Sensitivity analyses to account for pleiotropy were performed using MR-Egger regression and weighted median approaches. The weighted median test has been suggested as an alternative to the MR-Egger when the instrumental variable contains a small number of SNPs.

PheWAS. Gene ATLAS (http://geneatlas.roslin.ed.ac.uk/) was used as a lookup for outcomes from PheWAS analysis performed on UKB traits (54). The database contains data from >450,000 white British individuals, >31 million variants, and 778 traits; only ICD-10 traits were considered (n = 496). This information was used to derive a phenome-wide significance threshold, divided by the number of independent tests, i.e., 1.68 105 [0.05/(496*6)].

Pathway analysis. Reactome pathway knowledgebase (https://reactome.org/) was used to undertake pathway analysis (55). The Reactome Knowledgebase systematically links human proteins to their molecular functions, providing a resource that operates both as an archive of biological processes and as a tool for discovering unexpected functional relationships. Loci identified through distance-based clustering at a relaxed threshold of P < 5 106 from the GWAS analysis were included. These loci were mapped to pathways, and a P value was calculated on the basis of the overlap between the query and the pathway expression; an FDR correction was applied by the software.

C. elegans is an excellent genetic model for investigating whole-animal effects of alcohol (5658). Similar to humans, acute exposure to intoxicating alcohol induces a dose-dependent reduction in coordinated movement of C. elegans both in solution (59) and on solid agar (60). Strains of C. elegans were selected on the basis of the outcomes from the present GWAS at the level of P < 5 108 and having evidence of replication in GERA or being reported as genome-wide significant in other alcohol phenotype studies.

Phenotypic and RNA interference experiments were performed at 20C in a temperature-controlled room on young adult hermaphrodites selected from sparsely populated NGM (nematode growth media) plates. As we and others have previously demonstrated (59, 60), exposure to 400 mM external ethanol reduces coordinated locomotion of wild-type (Bristol N2) animals by ~70%. An external concentration of 400 mM ethanol is equivalent to an internal concentration of ~20 to 70 mM, which is equivalent to a blood alcohol level of ~0.1 to 0.4% and is consistent with levels of intoxication experienced by humans. Locomotion rate was the outcome of interest and was quantified by thrashing in Dents solution [140 mM NaCl, 6 mM KCl, 1 mM CaCl2, 1 mM MgCl2, and 5 mM Hepes (pH 7.4) with bovine serum albumin at 0.1 mg/ml] as previous described (59, 60). See the Supplementary Materials for full details.

All functional data are expressed as means SE. Thirty treated and untreated animals were analyzed and compared per strain per experiment. Statistical significance was assessed by one-way analysis of variance (ANOVA) with post hoc Bonferroni correction for multiple comparisons.

Supplementary material for this article is available at http://advances.sciencemag.org/cgi/content/full/6/3/eaay5034/DC1

Supplementary Methods

Table S1. Summary of final multivariable logistic regression model.

Table S2. Summary of genome-wide significant SNPs following distance-based clumping on the UKB cohort, and the replication cohort and meta-analysis outcomes.

Table S3. eQTL analysis outcomes.

Table S4. LD between the top eQTL SNP for any eQTL signal and the GWAS SNP.

Table S5. Variant-trait significant outcomes from PheWAS.

Table S6. Variants at 5 106 and submitted to the Reactome Knowledgebase.

Table S7. Mendelian randomization results for nominally significant outcomes in the IVW analysis and FDR outcomes using the IVW method.

Fig. S1. LocusZoom plots for lead SNPs from GWAS on alcohol phenotype in the entire cohort.

Fig. S2. Constitutive signaling by aberrant PI3K in cancer.

Fig. S3. Individual C. elegans b-Klotho genes outcomes.

References (6171)

This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

H. Kranzler, H. Zhou, R. Kember, R. V. Smith, A. Justice, S. Damrauer, P. S. Tsao, D. Klarin, D. J. Rader, Z. Cheng, J. P. Tate, W. C. Becker, J. Concato, K. Xu, R. Polimanti, H. Zhao, J. Gelernter, Genome-wide Association Study of Alcohol Consumption and Use Disorder in Multiple Populations (N = 274,424). bioRxiv 527929v1 [Preprint] (2019).

Acknowledgments: Funding: This work was supported by the Medical Research Council (grant number MR/S000607/1). Genotyping of the GERA cohort was funded by a grant from the National Institute on Aging, National Institute of Mental Health, and National Institute of Health Common Fund (RC2 AG036607). Analysis of GERA data was supported by NIH grants National Eye Institute grants R01 EY027004, R01 DK116738, and R21 AA021223 (E.J.). Author contributions: A.T., A.P.M., and M.P. conceived the project. A.T., J.C., and A.P.M. performed the discovery, replication, and in silico analysis. E.J., H.C., and J.Y. provided access to the replication cohort and data analysis. J.B. and T.K. provided access to C. elegans assays and performed the experiments. A.T., J.C., and J.B. produced data visualization. A.P.M. and M.P. supervised the project. A.T. wrote the original draft. All authors critically reviewed the drafts of the manuscript and approved the final version. Competing interests: The authors declare that they have no competing interests Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. The data from UKB were provided under license by UKB, who is the owner of the data. Requests for access to the data should be directed to UKB as per the material transfer agreement. Additional data related to this paper may be requested from the authors.

Read more from the original source:
Functional validity, role, and implications of heavy alcohol consumption genetic loci - Science Advances

Read More...

Healthy Headlines: Four common myths about genetic testing and why they are not accurate – User-generated content

January 20th, 2020 5:48 am

St. Elizabeth Healthcare

If you could take a simple test that would identify your risks of developing a potentially deadly disease so you could prevent it or treat it sooner, wouldnt you?

A proactive genetic test can do just that. Caroline Ewart, Genetic Counselor in the Center for Precision Medicine and Genomic Health at St. Elizabeth Healthcare, says, Understanding your family tree is important for your future health. Genetics play a big role in what diseases we will develop in the future. The more we understand the family, the more you can proactively do to protect your health.

Many people dont consider genetic testing because they think it is too expensive, not accurate enough, or doesnt screen for the diseases that run in their family. Ewart is helping us bust some of the common myths of genetic testing.

Myth #1: Genetic Testing is Too Expensive

When proactive genetic testing started, it was very expensive, and only a few select laboratories across the country performed the testing. Today, genetic testing is very affordable. Many health insurance companies will provide some coverage for testing, and the laboratories now have a limit on what they can charge.

A proactive screening in the Center for Precision Medicine and Genomic at St. Elizabeth Healthcare is just $395. That includes an initial genetic counseling visit, coordination of blood tests, carrier status screening, and a comprehensive consultation discussing your results. Individuals with a Flexible Spending Account (FSA) or Health Savings Account (HSA) may be able to use these funds to pay for the cost of the screening.

Myth #2: Genetic Testing Only Finds Breast Cancers

Its true, when genetic testing was in its infancy, we only tested for BRCA1 and 2 genes which detect breast and ovarian cancers, says Ewart. But the tests today are far more sophisticated. We now test for over 100 different gene mutations looking for a range of diseases and cancers.

Inherited conditions the tests screen for, include:

Breast cancer

Cardiovascular diseases

Colorectal cancer

Cutaneous melanoma

Gastric cancer

Ovarian cancer

Pancreatic cancer

Renal cell cancer

Thyroid cancer

Myth #3: Genetic Testing Doesnt Help the Treatment of Diseases like Cancer

Genetic testing is used not only to proactively screen for certain diseases, but it is used to treat cancer as well.

If you have been diagnosed with cancer, the gene mutation may guide treatment. It can also help your team manage increased risks of developing other types of cancers, says Ewart.

More importantly, the results of proactive genetic testing can guide your healthcare teams recommendations for screenings of cancer and cardiovascular diseases. This may include starting screenings at an earlier age, increasing the frequency of screenings or suggesting more advance screenings.

By screening early, we can find the disease early, when it is most treatable, says Caroline.

Myth #4: Genetic Testing isnt Accurate

Ewart says, Certainly there are limitations to testing, but our process is more than just a blood test. By gathering a thorough family history we can determine your risk factors for developing certain diseases, even if a blood test comes back negative.

At St. Elizabeth Healthcare, if you are found to be at high risk or test positive for genetic cancers, you are referred to the Heredity Cancer Clinic to develop a plan for future cancer screenings. They may also recommend your family members be tested, so you can get a full picture of your familys health. St. Elizabeth has many types of genetic screenings. To find the one that best fits your needs, pleasestelizabeth.com/dna or call 859-301-GENE (4363).

View original post here:
Healthy Headlines: Four common myths about genetic testing and why they are not accurate - User-generated content

Read More...

18 Amish young people died suddenly; Mayo Clinic identified genetic problem believed to be responsible – LancasterOnline

January 20th, 2020 5:48 am

The Mayo Clinic has identified a genetic problem believed to have caused sudden death in 18 of 23 Amish young people who had it, according to media reports.

The study published recently in JAMA Cardiology said researchers studied two large Amish extended families that reported multiple sudden deaths, including four siblings with exercise-associated sudden deaths.

"With the help of new technology that wasn't around when they first started looking into the case, the team learned that these Amish children had all inherited the same genetic mutation from both of their parent," CNN reported.

Now that the problem has been identified, Popular Science reported, potential couples can be tested to see whether they are both carriers, and people who are at risk of sudden death because of the problem can have a defibrillator implanted.

One of the best-known medical facilities working with the Amish and other Plain community people to identify and treat genetic diseases is in Lancaster County the Clinic for Special Children in Strasburg.

The clinic wasn't involved in the study, according to spokeswoman Kelly Cullen. However, she said, lab director Dr. Erik Puffenberger checked its thousands of records for RYR2, the gene involved. None were affected, she wrote, only three were carriers of the gene, and only one of those people was local to Lancaster County, "demonstrating that the RYR2 genetic variant is very rare in our area."

Success! An email has been sent with a link to confirm list signup.

Error! There was an error processing your request.

However, she wrote, the clinic is planning to add RYR2 to the next version of its Plain Insight Panel, which screens for thousands of genetic variants known to cause problems across the Plain communities of North America.

See the article here:
18 Amish young people died suddenly; Mayo Clinic identified genetic problem believed to be responsible - LancasterOnline

Read More...

The Case Of Pamela Maurers Murder Went Cold For Decades, Then Genetic Sleuthing By Parabon Helped Crack It – CBS Chicago

January 20th, 2020 5:48 am

CHICAGO (CBS) Despite exhaustive work by detectives, the murder of Pamela Maurer was left unsolved for more than four decades. Last year, a relatively new form of genetic sleuthing began to put together the pieces of the mystery in a matter of days.

DuPage County investigators provided genetic material preserved from the Maurer crime scene to Maryland-based Parabon NanoLabs. Pamelas body was found in Lisle in January of 1976. She had been sexually assaulted and strangled. She was last seen alive the night before her body was found, when she told friends she was going to a restaurant to buy a soft drink.

First, Parabon, led by chief genetic genealogist CeCe Moore, used the DNA to create a snapshot genotypewhich predicts a persons physical traits, such as eye, skin and hair color, and even the shape of a face.

The composite created from that test looks remarkably similar to Bruce Lindahl, a suspected serial killer who police now say killed Maurer. Lindahl died in 1981.

But the testing didnt stop with just a picture. The hard work had only just begun.

Moores team used the DNA to reverse engineer Lindahls family tree.

Parabon loaded the DNA sample from the Maurer crime to a website called GEDmatch and began a form of genetic treasure hunting. GEDMatch is a site where users can upload their genetic testing results, done by companies like 23AndMe and Ancestry.

Typically, Moore said, they find similar DNA from distant cousins of a suspect and build back from there.

We are looking just for people who are second, third, fourth, fifth cousins and beyond, Moore said. Typically we are not getting close matches to close family members.

Basically, Parabon is reverse engineering the family tree of the suspect based on who they are sharing DNA with, Moore said.

Moore said she found multiple distant cousins that led to Lindahl, up to 20 matches and put those puzzle pieces together.

It is almost never a single match that leads to an identity. Its a group of matches to see how they all connect to each other.

My work, and my teams work is really about providing answers to these families for years and decades, Moore said.

She said part of the hunt is luck. In this case, the data allowed them to find a suspected match to Lindahl in a few days.

But Parabons work didnt solve the case. Detectives still needed more proof. So, they got a court order to exhume Lindahls body and extract DNA from his remains.

The result was a match.

The odds of the DNA belonging to somebody else are 1 in 1.8 quadrillion, DuPage County States Attorney Robert Berlin said this week.

This was the second case Parabon has done in Illinois, but the first in the Chicago area.

Last year, Moores work led to murder charges against Michael Henslick, who police say killed Holly Cassano. She was found fatally stabbed in her home in Mahomet, Ill., on Nov. 2, 2009.

That case is expected to go to trial next month, Moore said. Parabon has so far worked on 93 cases with police across the country in the past two years. The most famous charges against the suspected Golden State Killer, Joseph James DeAngelo.

Critics find the practice controversial and a potential invasion of private DNA data. Moore says the benefit to the public, ensuring that killers are put behind bars, and the fact that families get some resolution, far outweigh those concerns.

I feel that the good that has been done is really immeasurable to public safety, Moore said.

Lindahl died at age 28 in 1981 after he bled to death while stabbing another victim, Charles Huber. The coroner said his knife wounds were accidentally self inflicted.

RELATED: Those Who Remember Lindahl Say He Gave Them The Creeps

Police now say he may have killed at least two other women.

Lindahl was charged with raping Deborah Colliander, who manged to escape from the attack. However, two weeks before Lindahls trial, Colliander disappeared after leaving her job at a hospital.

The case against Lindahl was dropped.Collianders body was found on April 28, 1982in a field on Oswego Township.

Investigators also think Lindahl may have something to do with the disappearance of Deborah McCall, a student at Downers Grove North. She was last seen alive in November 1979. Photos of her were found in one of Lindahls residences.

And there may be other victims in the 1970s and before his death, police said. The new evidence will be used to open additional investigations.

Investigators set up two tip lines: (630) 407-8107 (DuPage States Attorney) and (630) 271-4252 (Lisle police).

Read the rest here:
The Case Of Pamela Maurers Murder Went Cold For Decades, Then Genetic Sleuthing By Parabon Helped Crack It - CBS Chicago

Read More...

Donor-conceived people lobby UN for access to their genetic heritage – UNSW Newsroom

January 20th, 2020 5:48 am

Giselle Newton, a PhD research student at UNSW, is one of 16 donor-conceived and surrogate-born people from around the world who are leading a renewed push to change laws which govern their access to information about their genetic heritage.

For the first time, the group told their own stories at a historic visit to the United Nations to mark the 30-year anniversary of the Convention for the Rights of the Child in Geneva on November 19.

They presented their five recommendations* to the Human Rights High Commissioner Michele Bachelet, and received a standing ovation from the audience.

We highlighted the consequences of ignoring the voices of those most affected by these practices, Ms Newton says. Donor-conceived people are experts on this issue and our voices need to be listened to and acted upon.

International Social Services representative Mia Dambach led the workshop on biotechnology at the UN, and says there is an urgent need for the development of global standards.

It is hoped that this will not be the last time the voices of those most affected are heard representing as many experiences as possible, Ms Dambach says.

Ms Newton was conceived in the Northern Territory by sperm donated in Western Australia, before being born in NSW.

She says her parents did the right thing by telling her at a very young age that she was donor-conceived.

From day dot, its really important for children to know they were donor-conceived, Ms Newton says. And that they have the ability to contact donors and donor-conceived siblings.

Laws

In Australia, laws differ between the states.Victoria is leading with legislation implemented in 2017 that allows all donor-conceived people the chance to retrospectively access information about their biological parents.

It would be good if other states really pull up their socks and follow suit, Ms Newton says.

But in NSW, recent changes to legislation allow donor-conceived children born after January 1, 2010 the ability to track down their biological parent(s), once they turn 18. Those born before this date can only access non-identifying markers such as the ethnicity, physical characteristics, medical history, and the sex and year of each of the donors offspring.

In WA, once a donor child turns 16, records relating to his or her lineage are open for them to access. But for those born before 2004, they need to have the donors permission before they can obtain the missing pieces to their biological puzzle.

What Ms Newton and others like her want is the power to access information about their identity and origins including information about their donors and donor-conceived siblings.Being disconnected from your biological history can have drastic consequences in terms of identity, she says.

It is this emotional element that US doctor William Pancoast did not foresee when he made the first successful experiment by artificially inseminating a woman with the sperm of one of his most attractive medical students in 1866.

UNSW PhD study

While estimates have suggested that there are between 20,000-60,000 donor-conceived people in Australia, Ms Newton says that there has been very limited empirical research that explores life as a donor-conceived adult in Australia.

In her doctoral thesis at UNSWs Centre for Social Research in Health, she will examine what services and support are available to donor-conceived people with a particular focus on the role of peer support in online and offline contexts.

I am really fascinated by the idea of how connection with peers can contribute to a sense of belonging, she says.

UNSW Associate Professor Christy Newman has highlighted the importance of Ms Newtons research for the support needs of donor-conceived adults. She hopes it will help inform policy and practice responses to this increasingly growing group of people in Australia and around the world.

Ms Newton will be recruiting donor-conceived people to participate in a national online survey and interviews in early 2020.

(To participate or find out more about the study)

An international concern

Netherlands-based Joey Hoofdman was among those who participated at the UN conference in Geneva. Mr Hoofdman found out he has at least 75 half-siblings via the doctor who treated his parents for fertility problems in the 1980s. The 32-year-old only discovered in 2017 that he was donor-conceived.

Mr Hoofdman says he blames his biological father for having crossed a medical-ethical boundary by using his own sperm during a time when there was insufficient supervision and a lack of regulation.

We need to make agreements on an international level so we can prevent this from ever happening again.

*Recommendations

Ms Newton, Mr Hoofdman and others put forward the following to the UN:

1) Ensure the right of donor-conceived and surrogate-born children to access information about their identity and origins regardless of when these children were conceived and born, and to preserve relations with their biological, social and gestational families.

2) Ensure that comprehensive and complete records of all parties involved in the conception of the child be held by the State in perpetuity for future generations.

3) Respect and promote the full and effective enjoyment of all the rights of donor-conceived and surrogate-born children in both the immediate and longer terms.

4) Ensure that the best interests of the child be the paramount consideration in all relevant laws, policies and practices and in any judicial and administrative decisions. This requires a best interests assessment pre-conception on a case-by-case basis.

5) Prohibit all forms of commercialisation of gametes, children and surrogates including, but not limited to, the sale and trafficking in persons and gametes.

Go here to see the original:
Donor-conceived people lobby UN for access to their genetic heritage - UNSW Newsroom

Read More...

BTYSTE 2020: From eco-friendly dollhouses to the genetics of clever dogs VIDEO – Siliconrepublic.com

January 20th, 2020 5:48 am

We visited theBT Young Scientist and Technology Exhibition again this year, getting the chance to chat to some of the countrys brightest students.

There were project posters stretching to all corners of the main hall at the RDS, filled with excited participants waiting for their visit from the judging panel.

Hugh Murtagh from Coliste Mhuire in Westmeath took us through hisA-Ok project a discreet wristband that students with autism can wear to let their teacher know if theyre feeling overwhelmed at school.

I have autism and I know just how hard it is to try and focus in class when you feel overwhelmed. I want to try and help people like me and people who also have autism, he said.

We also learned about an eco-powered dollhouse with the potential to teach children about climate action, how mental health can be impacted by climate change, and whether genetics affects how clever a dog breed is.

>> READ MORE

Words by Lisa Ardill

More:
BTYSTE 2020: From eco-friendly dollhouses to the genetics of clever dogs VIDEO - Siliconrepublic.com

Read More...

Personalized nutrition could be the next plant-based meat, worth $64 billion by 2040, says UBS – CNBC

January 20th, 2020 5:48 am

Imagine receiving customized nutrition advice based on your personal biologic or genetic profile. That's the "future of food," according to a UBS analyst, who sees diet personalization as the next plant-based meat.

Personalized nutrition could generate annual revenues as high as $64 billion by 2040, the firm said. Plus, big-name companies such asApple, Uber and Amazon could benefit from the massive growth opportunity.

"With heightened health awareness among consumers, yet also more people suffering from ailments which are attributable to poor nutrition, there is growing demand for solutions that can improve individual nutritional choices," said UBS analyst Charles Eden in a note to clients on Tuesday. "Personalised nutrition ... represents a potential such solution."

Personalization is a theme that has swept many industries in recent years. An increasing number of businesses are sending out questionnaires to customers to create profiles for their likes, dislikes and needs. Customized weight loss programs, clothing and shopping companies, makeup brands, vitamin providers, are just a few to have delved into an industry with massive growth potential, said Eden.

UBS's theory is that food, medical diagnosis, technology and food delivery companies can all benefit from this industry. From services as simple as questionnaires, blood samples and genetic profiling, companies can capitalize on society's shift in support to improved nutritional habits.

UBS said it sees four major industries capitalizing on this opportunity: Medical diagnosis firms to extract and interpret test results; Technology companies to develop wearable tech and integrated platforms for users to receive ongoing interactive feedback; Food producers to meet nutritional demand; And, food delivery companies to meet consumers' increasing demand for convenience.

Illumina, Thermo Fisher Scientific, Apple, FitBit, Nestle, 23andMe, Ancestry.com, Unilever, Amazon Fresh and Uber Eats are some of the companies UBS mentioned as being in the game.

The personalized nutrition opportunity has not been lost on current food company incumbents.

"Nestl, the world's largest food company, has identified personalised nutrition as a major growth opportunity and has made a number of investments in the space," said Eden.

Nestle puts money into research from brain health, pediatrics, chronic medical conditions, obesity, malnutrition, and gastro-intestinal health.

Companies like Apple have bet big on personalized health, which could make the Tim Cook-led tech giant a potential pioneer in the personalized nutrition industry. Apple has identified the health care industry as an area of innovation, with its popular Apple Watch providing real-time personal health data to its wearers.

"The Apple Watch is already being used to study heart rates, perform ECGs, study eating disorders, track fitness and many other health metrics. Health data in Apple Watch could be combined with genetic information to offer personalized nutrition," said Eden.

Even Amazon Fresh, the e-commerce giant's grocery delivery service, and Uber Eats are well-positioned to win in this budding industry, said UBS.

"Delivery will allow for increased convenience and time savings in food preparation (e.g. partnering with Delivery Hero or Uber Eats to deliver the exact meal which has been freshly prepared to meet the needs of that individual consumer)," said Eden.

Eden said affordability is the most obvious constraint on the personalized nutrition scenario in the near term. Healthier foods can be more expensive than mass produced box items, and the personalization will also come with a cost.

Scientific evidence on the merits of personalizaiton are also lacking, UBS said.

Data privacy is a hurdle as well if consumers don't want their medical, biological or genetic information shared with other parties.

with reporting from CNBC's Michael Bloom.

Continued here:
Personalized nutrition could be the next plant-based meat, worth $64 billion by 2040, says UBS - CNBC

Read More...

The Secret That Helps Some Trees Live More Than 1,000 Years – The New York Times

January 20th, 2020 5:46 am

The ginkgo is a living fossil. It is the oldest surviving tree species, having remained on the planet, relatively unchanged for some 200 million years. A single ginkgo may live for hundreds of years, maybe more than a thousand. Theyve survived some of our worlds greatest catastrophes, from the extinction of the dinosaurs to the atomic bombing of Hiroshima.

So whats the secret to their longevity?

In the rings and genes of Ginkgo biloba trees in China, some of which are confirmed to be more than 1,000 years old, scientists are starting to find answers.

In humans, as we age, our immune system begins to start to not be so good, said Richard Dixon, a biologist at the University of North Texas. But in a way, the immune system in these trees, even though theyre 1,000 years old, looks like that of a 20-year-old.

He and colleagues in China and the United States compared young and old ginkgo trees, ranging in age from 15 to 1,300 years old, in a study published Monday in the Proceedings of the National Academies of Science. By examining the genetics of the vascular cambium, a layer or cylinder of living cells behind the bark, they found that the ginkgo grows wide indefinitely through old age.

Thats because the genes in the cambium contain no program for senescence, or death, they say, but continue their program for making defenses even after hundreds of years. Old trees also produce just as many seeds and their leaves are just as resourceful as those of young trees. Though it has yet to be tested, the researchers believe other old trees think of the 4,800-year-old bristlecone known as Methuselah in eastern California may have a similar pattern of genetic programming.

Although ginkgos live long, they do age. The trees grow up and out: Up, with a cell-generating region called the apical meristem, and out, with the vascular cambium. Over time, weather or other things damage the apical meristem, limiting a trees height. And each year, leaves die and fall off.

But the cambium, contained within the trees trunk, remains intact and active. Cell division tends to slow down after the age of 200, they found. But the cells are still viable. They generate defenses and carry water and nutrients so the tree grows and stays healthy.

Sometimes trees may be reduced to just hollow stumps, but with the cambium intact, they can still produce leaves and flowers or even live as stumps.

Eventually, even ginkgo trees die. But a big question remains: Why?

Essentially, trees like ginkgo could live forever, says Peter Brown, a biologist who runs Rocky Mountain Tree Ring Research and was not involved in the study. Being modular organisms, every year theyre putting on new wood, new roots, new leaves, new sex organs, he said. Theyre not like an animal, like us. Once were born, all of our parts are there, and at a certain point they just start to give out on us.

The trees dont necessarily die of old age, he says. Something pests, drought, development kills them first.

He and others presume that studies on other trees like redwoods or Methuselah would produce similar results. And though humans are quite different from trees, contemplating them serves some purpose.

Peter Crane, an evolutionary biologist and author of Ginkgo: The Tree that Time Forgot, said contemplating long-lived trees might help us to see further into the future than many of us tend to look.

Its kind of a way of calibrating how quickly our world is changing and reminding us that we shouldnt always be thinking of the short term.

Continued here:
The Secret That Helps Some Trees Live More Than 1,000 Years - The New York Times

Read More...

Good health through the decades – Independent.ie

January 20th, 2020 5:46 am

While I am all for having a good time, attention needs to be paid to alcohol consumption - alcohol contains 7kcal per gram, which is even more than in carbohydrates, and almost as much as in fat, weight-for-weight! Excessive alcohol is a huge contributory factor to obesity and being overweight, it is almost like drinking liquid fat! Alcohol also dissolves your resolution, leaving you more likely to overeat and gain even more weight.

Nutrition plays a major role in determining the switching on or off of certain genetic expressions, determining both our own future health and the health of generations ahead. It's not just excess weight that causes problems, excess alcohol, smoking, and a diet heavy in processed foods and sweets, all contribute to a lack of nutrients, altering hormone production, cell regeneration and cellular genetics. A diet rich in colourful vegetables benefits the body in more ways than you know!

The fountain of youth is not as far away as perhaps you once thought; it's in your hands every day of your life. We all have the ability to shape our futures and encourage longevity, so why not use the new year and the start of the next decade to reconnect and strengthen?

A most happy and healthy New Year to you all.

OUR 30s

Hopefully when we reach our 30s, we are not in a situation where we are trying to reinvent our health after damage created during our earlier years.

Most people are thinking about starting a family in these years, so it is especially important for parents and prospective parents to be in good health to give their children the best opportunity for a long and healthy life. Nutrition is of utmost importance for both men and women. Folate, Vitamins B12, B6 and B2 are of particular importance at this time for correct DNA methylation, allowing for a host of functions, including neurotransmitter production in the unborn.

Women of childbearing age should choose plenty of fresh, green, leafy vegetables, and supplement, if needed, with a methyl folate, a more natural form (of folate) that is more readily absorbed by the body.

Sleep is a cornerstone of good health, but recent studies have shown that 80pc of the Irish population is sleep-deprived. It is all too easy to become run down, make poor food choices and become injured when you are sleep-deprived.

Our bodies recover and rebuild tissue while we are asleep. Our brain and organs need rest in order to function properly. No matter how well your children sleep, it is not an easy task to maintain balance between family life, work, social occasions and personal development, but simply prioritising good health rather than sitting and watching TV when the kids have gone to bed will have far-reaching effects.

We are more productive when we have adequate sleep - our mental health is better, our diet is healthier and our cognitive capabilities score higher - so go to bed!

OUR 40s

During our 40s, most of us are still juggling a busy lifestyle, and this is also the time when we feel the need to make our mark on the world, to leave that legacy. The demands of a busy lifestyle can take over, but you must remember the cornerstones of good health. Nutrition, sleep, activity and ensuring good mental health are crucial to a long, happy and healthy life.

It is also worth remembering that age is not an excuse for weight gain - visceral fat and the inflammation it produces are the driving forces behind all major illnesses in the world today.

People in their 40s are now presenting with illnesses previously diagnosed in the 60-plus age group. Don't let the 'middle-aged spread' take hold!

Monitor your blood pressure, cholesterol and blood sugars. Don't forget there is only one you; take time out, come back to base and reset whenever and as often as it is needed!

OUR 50s

Many physiological changes occur during our 50s, for both men and women. A once active sex life may dwindle in these years, but a healthy sex life actually improves the quality of life both physically and emotionally. It is important for us all to have a strong bond in our relationship, and sex is proven to create and uphold this.

For men, erectile dysfunction may be an issue at this time of life, most likely caused by obesity and side effects of prescribed drugs. Please do not feel embarrassed by this. Seek advice from your GP and get the issue resolved!

For women, the menopause causes lower oestrogen levels, resulting in a barrage of 'side effects'. Personally, I am against taking medication unnecessarily, but I think all women over the age of 50 should take a hormone replacement, as the pros far outweigh the cons.

The loss of oestrogen associated with menopause has been linked to a number of illnesses such as osteoporosis, heart disease and an increased risk of developing Alzheimer's disease. Vaginal dryness can be a major hindrance to your sex life, but there are new, effective therapies available, so, again, please speak with your GP or gynaecologist to resolve any issues.

OUR 60s (and beyond)

In later years, we take time to reflect on times past and on what we have achieved. Although the physical body may slow down a bit and we may be in a position to slow down our working life, we always need good physical and cognitive health.

Companionship has been shown to be one of the greatest assets in maintaining good mental and cognitive health. We need stimulation, not isolation!

Now is the time to take on new challenges, meet new people, and spend time with those we love. The brain thrives on activity, and is learning throughout our whole life.

At this time of life, it is crucial to actively improve one's balance. Falls at this stage of life are the leading cause of injury and mortality. Simple exercises repeated on a regular basis will have a lasting, positive effect, as well as actively keeping a good level of fitness.

Sleep is also vital, as the body's need for rejuvenation and repair is high, so ensure you are getting your eight hours.

As we age, our sensitivity to thirst lessens, and dehydration can occur rather rapidly. Just a 2pc dehydration rate reduces our cognitive function, reduces immune function and thickens blood flow. If you are thirsty, you are already dehydrated! Sip on water regularly to avoid this. Tea and coffee can dehydrate, so try not to over-consume these. Nutritionally speaking, vitamin D becomes more difficult to absorb, so a good supplement would be worthwhile. B vitamins aid energy production and cognitive function - in fact, a link has been shown between a deficiency in B vitamins and dementia-related illnesses.

A diet rich in a wide variety of whole grains, fruits and vegetables, as well as quality protein sources, is the best way forward - at every age.

BY DR EVA ORSMOND

Sunday Indo Life Magazine

See the rest here:
Good health through the decades - Independent.ie

Read More...

‘If there’s any secret to aging, it’s bowling’: Vancouver bowler turns 100 – CTV News

January 20th, 2020 5:46 am

VANCOUVER -- If the key to a long life is staying active as you age, then bowling is Ethel Morley's fountain of youth.

The Vancouver resident turned 100 on Saturday, surrounded by friends and family at Commodore Lanes, where she's a dedicated member of the league.

"Last Monday, it was snowing out," recalled league manager Ken Hayden. "We have about 40 people in the league. It starts at 1 o'clock. I look over, and who is coming down the stairs, but Ethel?"

"Half the people half her age couldn't make it, but Ethel managed to make it here on the bus."

Morley's daughter Toni Crittenden was among those there in slightly nicer weather on Saturday to celebrate her milestone. Crittenden said relatives made the trip from Manitoba, Calgary, and even California for the occasion.

"We've watched her and we've been amazed at every birthday that she's still bowling," Crittenden said. "It's pretty inspiring."

Morley said it's "wonderful" to reach the century mark, though it was unexpected. Her husband Walter died in 1997, after 58 years of marriage.

Her great-grandson now bears her late husband's name. And little Walter is already starting to show an interest in the game, according to his father.

"I think he might be following in his great grandma's footsteps," said Neal Pickering, Morley's grandson. "He's really getting into it. He's got some little plastic bowling pins."

Pickering said he hopes he got his grandmother's genes when it comes to longevity, but she says the secret isn't genetics.

"If there's any secret to aging, it's bowling," Morley said. "I like the people that come in, the friendship with all the people that bowl. Its good exercise."

With files from CTV News Vancouver's Allison Hurst.

Read the rest here:
'If there's any secret to aging, it's bowling': Vancouver bowler turns 100 - CTV News

Read More...

Colorado is one of the healthiest states in the country, but health outcomes vary widely by county – Brush News-Tribune

January 20th, 2020 5:46 am

Colorado has one of the healthiest populations in the nation, but that doesnt mean some resolutions arent in order for 2020, assuming they havent been already attempted and cast aside.

Residents of Logan, Morgan, and Prowers counties may want to consider watching what they eat and shedding a few pounds. Make that a lot of pounds. Residents of Bent, Saguache and Adams counties need to get better at keeping something else out of their mouths cigarettes.

And residents of Denver, Boulder and pretty much all the ski-resort counties, please do your livers a favor in 2020 and cut back on the binge drinking.

SmartAsset, a personal finance firm, looked at those three behaviors, along with rates of health insurance coverage, longevity and access to a physician to come up with an overall health score that was used to rank 48 of Colorados 64 counties. There wasnt sufficient data in the 16 counties excluded.

Our study identified the healthiest counties in Colorado by considering length of life, health behaviors and healthcare access, said AJ Smith, vice president of financial education at SmartAsset.

A goal of the SmartAsset study was to help consumers understand how certain behaviors might impact life insurance premiums in different areas, Smith said. But the study offers a trove of public health information, including a comparison of lifespans.

Douglas County ranked as the healthiest county in the state, followed by Boulder, Pitkin, Broomfield and Eagle counties. Get outside of the ski resort areas, however, and rural residents in Colorado tend to have lower health scores and shorter lifespans.

Rural doesnt always mean healthier, which may surprise some Front Range city dwellers who aspire to trade the stress of congested roads and demanding workloads for clean air and open vistas.

In Douglas County, which had the highest health score in Colorado, about 3,494 years of life are lost before age 75 per 100,000 residents. Only Pitkin, Summit and Eagle counties show fewer hours of life lost prematurely, in the low 3,000 range.

At the other extreme, Huerfano County residents lost 13,227 years of life prematurely or nearly four times as many as in Douglas. Las Animas County residents lost 12,439 years of life to premature deaths and in Conejos, it is 10,271 years of life lost.

Granted, not everybody gets to live to age 75. But why should someone living in Walsenburg or Trinidad face higher odds of early death than someone in Highlands Ranch or Aspen?

It is totally tragic, said Emily Johnson, director of policy analysis at the Colorado Health Institute.

There is an old saying that people spend their health to accumulate wealth, and then spend their wealth to recover their health. But the reality is that having more wealth allows someone to maintain better health.

What Douglas and the ski resort counties share in common are higher median household incomes, while the counties with the lowest health scores have some of the lowest household incomes in the state. That leads some to conclude that improving health is an economic development question, not just a behavioral one.

There is a lot there that is pushing you to poor health when you are lower-income, Johnson said. It ranges from the stress of making the rent to whether a person feels safe going for a jog in their neighborhood.

Higher-income households have better access to resources that promote and maintain health and more options for off-loading stress, she said. And they are more likely to have jobs that come with health insurance.

Douglas County has the lowest uninsured rate in the state at 3.7%, while Broomfield, Gilpin, Clear Creek and Jefferson counties all had uninsured rates below 7%. El Paso, Boulder, and Larimer counties, the larger population centers outside metro Denver, had uninsured rates just above 7%.

At the other extreme, 17.5% of residents in Saguache County lack health insurance coverage, and 15.3% of Garfield County residents arent covered. A lack of coverage can cause people to delay visits, allowing chronic conditions to go untreated.

And a lack of health insurance coverage doesnt necessarily motivate people to take fewer risks with their health, even though the consequences for them are more severe if they dont stay healthy.

If we were purposely logical creatures, we would never smoke or drink, Johnson said.

As executive director of the Tri-County Health Department, which covers Douglas, Arapahoe and Adams counties, John Douglas has a front-row seat on how economic differences play out in public health outcomes.

Douglas has Colorados highest health score and the nations sixth-highest, a top ranking other studies have confirmed. It also has Colorados highest median household income at $115,314. Arapahoe ranks 14th in Colorado and 110th nationally on its health score. It holds the 10th spot in Colorado for household income at $73,925. Adams ranks 36th on its health score locally and 722nd nationally. It has the 17th spot in Colorado on household income at $67,575.

Heres just one example in how county wealth plays out in creating different options to improve health.

Douglas County has 3.7 times the concentration of fitness and recreational sports workers than the country as a whole does, so many it ranks fifth in the U.S., according to the U.S. Bureau of Labor Statistics.

Arapahoe County has 1.85 times the concentration, not as heavy as Douglas, but nearly double the U.S. average. Adams County, by contrast, matches the national average. And Lake and Montrose counties they have about as half as many fitness workers as would be expected.

When SoulCycle, the trendy indoor cycling chain out of New York, opened its first Colorado location, it didnt pick Aurora or Thornton. It set up shop in Cherry Creek, Denvers ritziest retail district.

People who do well in life have the resources to better educate themselves about staying healthy, and they likely have a stronger motivation to do so, said Douglas. But the equation is a complex one, with a lot of variables.

A 2007 study published in the New England Journal of Medicine linked about 40% of health outcomes to personal behaviors, such as putting on too many pounds, smoking and substance abuse, said Gabriel Kaplan, chief of the health promotion and chronic disease prevention branch at the Colorado Department of Public Health and Environment.

Genetics, including traits that leave some at a higher risk of cancer or heart disease, explains about 30% of health outcomes. Social conditions such as economic opportunities and educational attainment account for about 15% of the equation. Health care access, something public health officials have focused heavily on, only contributes about 10%, while environmental conditions, such as pollution, contribute about 5% of the mix.

But it is important to note social conditions tie into personal behaviors. Someone born in a town where teenagers smoke at an early age or drink heavily is likely to pick up life-shortening habits and addictions. Likewise, a worker in an area with poor job prospects or a farmer dealing with wild swings in crop prices may try to cope with stress in unhealthy ways.

If the only store where you can get produce is a convenience store, you are not as likely to have a diet with fruits and vegetables, Kaplan said. We need to make sure communities are set up to promote health. It is not just a matter of individual choice.

Alcohol consumption is one behavior where higher incomes dont correlate with healthier behaviors. Some of the most well-off counties in Colorado have the highest rates of self-reported excessive drinking.

We have been talking about this in public health circles, Douglas said. It is an underappreciated and ignored health issue.

Excessive drinking involves drinking heavily in a short period of time with the express goal of becoming intoxicated. The National Institute on Alcohol Abuse and Alcoholism defines it as five or more drinks in a two-hour period for men and four or more drinks for women.

Deaths in the U.S. from binge drinking have more than doubled the past two decades, with the sharpest increases for women and the middle-aged, according to the Center for Health Progress. That statistic that sheds a whole different light on the mommy drinking culture.

Boulder County, despite its reputation as a health mecca, had the second-highest rate of excessive drinking in Colorado at 23.6%, according to SmartAsset. The University of Colorado Boulder, which regularly appears on rankings of the nations top party schools, might drive that number up, but students alone arent to blame for Boulders lack of sobriety.

Only Denver County, with its abundant bars and craft brewers and millennials who frequent them, had a higher rate of people who engage in excessive drinking at 25.7%.

Denver has a drinking problem, Douglas said. Good luck, however, getting Denver or Boulder to admit they have a drinking problem.

Outside those two, the next five counties with the highest rates of excessive drinking are all ski resort counties. Drinking after a day on the slopes might be a tradition for many, but it appears the locals keep the party going even when the tourists are gone.

Huerfano County, which ranked 47th out of 48 on its health score, had an excessive drinking rate of 15%, a full 10 percentage points lower than Denver and the second-lowest in the state. It tied with Otero and only trailed Saguache. All three counties are among the poorest in Colorado.

Every five years, the 53 public health agencies in the state are tasked with putting together a community health assessment which they use to identify the top priorities for the following five years, said Theresa Anselmo, executive director of the Colorado Association of Local Public Health Officials.

Anselmo urged those who look at health statistics and rankings not to play the blame game and realize that for many people, achieving better health requires more than a resolve to do better.

Maybe a community cant attract a physician no matter how hard it tries and the national grocery chains wont come anywhere near. That leaves residents with fewer options to eat healthy and fewer resources for one-on-one counseling about weight management.

Rural areas tend to have older populations, who are more prone to health problems, Anselmo notes.

And self-selection plays a part. Colorados reputation draws in those looking for a healthy lifestyle, but they tend to settle along the Front Range. And even within the state, people who can afford to do so move into healthier communities.

Folks that have more means end up living in healthier places, said Douglas. You dont have to live near the Suncor refinery. You can live in Castle Rock.

While Colorado may do better than other states on physical health measures, mental health remains a challenge, which is reflected in higher rates of suicide and substance abuse, Kaplan said.

Stress is often a driver behind behaviors like smoking, binge drinking, substance abuse and overeating, and the state is focused on providing people with coping skills to deal with stress.

Behavior is not just a matter of choice for people. We look at strategies that make it easier for people to make healthy choices, said Kaplan.

For example, the state has invested heavily in the Colorado QuitLine, which helps those who are trying to kick the nicotine habit through coaching and medications. In 2004, 23% of state residents smoked tobacco. Thanks to higher tobacco taxes, indoor smoking bans and more resources dedicated to quitting, that figure is below 15%.

That reduction is part of a larger national trend resulting in a big decline in lung cancer deaths.

For us, it is all about trying to help everyone in the state to have the chance to have a healthy life, to have a long and fruitful life, Kaplan said.

Subscribe to our bi-weekly newsletter to get health news sent straight to your inbox.

The rest is here:
Colorado is one of the healthiest states in the country, but health outcomes vary widely by county - Brush News-Tribune

Read More...

More injuries seem to happen to certain NFL players: examining the fairness of the injury-prone label – The Athletic

January 20th, 2020 5:46 am

Injuries happen. But sometimes, more injuries seem to happen to certain players. Of course, the sporting world has a term for that player injury prone. In the NFL, that can be a tough label to shed.

The term is used frequently, but rarely with regard to the cause of injury or the circumstances behind it. Take for instance, Carson Wentz. Former players and the media questioned Wentzs durability after he left his first playoff game with a concussion. In most cases, as with Wentz, injuries arent the fault of players, trainers or strength and conditioning coaches, but rather the nature of playing a sport where large, fast individuals regularly crash into each other.

We all use that term, said Dr. James Andrews, but we dont have any scientific basis for it in most cases. We prefer to say, injury-unfortunate rather than pinning that (injury-prone label) on somebody. Psychologically, you cant throw that word around.

Injuries can...

Here is the original post:
More injuries seem to happen to certain NFL players: examining the fairness of the injury-prone label - The Athletic

Read More...

North Wales stockman’s unusual route to the top – Wales Farmer

January 20th, 2020 5:46 am

By Debbie James

The journey to running a large-scale dairy herd has been an unconventional one for James Evans.

As a teenager, James dreamed of becoming an actor, honing that talent on stage with the YFC.

But, having failed to secure a university place to study drama, he took umbrage and set off for Canada, where he spent a year working as a skiing instructor at Whistler.

He describes that period as a good life experience but the interest in farming he thought he didnt have surfaced so he headed home and enrolled at Harper Adams where he studied agriculture.

I went there knowing nothing and perhaps left knowing even less because I failed the degree! he laughs.

But what he did gain from the course was an excellent industry placement with a feed company in Nantwich, where he developed an interest in feed rationing and gained a good understanding of the materials fed to dairy cows.

James also milked every other weekend, at his familys 385 hectare (ha) mixed farming business at Llangedwyn, Oswestry.

His lightbulb moment when he first realised that he genuinely wanted to farm came in August 2013.

We sat down as a family and discussed the future and I decided then that I wanted to give farming a go, recalls James, who was given responsibility for the dairying side of the business.

Now aged 28, he has grown the herd from the 275 Holsteins milked in 2013 to the 630 in the herd today, aiming to expand cow numbers to 750-800 in the next 18 months.

Cows are fully housed and milked three times a day at 5am, 1pm and 9pm producing an average milk yield per lactation of 12,200 litres at 3.7 per cent butterfat and 3.3 per cent protein.

One of James first decisions was to introduce three-times-a-day milking that resulted in an immediate and big improvement in milk yield.

As the business is seeking to drive up cow numbers, 45 per cent of the herd consists of first lactation heifers.

James is using genetics to improve the herd. We want animals with better fertility and longevity and genetics can help us to achieve that, he believes.

All heifers are genomically tested as a means of assessing traits such as health, type, milk and constituents, to inform decisions on which animals to breed herd replacements from.

Cows are fed a total mixed ration (TMR) twice a day, with 55 per cent of the ration coming from homegrown silage and maize, topped up with a high-quality protein blend, rolled wheat, liquid feeds, protected fats and a bespoke mineral blend to create a balanced ration.

For the last two years, a multicut silage system has been in place in an attempt to improve forage quality and drive cow intakes to 12-12.5kg a head a day.

About 25 per cent of the 162ha silage platform is reseeded annually using a 50/50 mixture of diploid and tetraploid varieties with narrow heading dates, from May 28 to June 4, to ensure everything grows at the same rate.

Another key focus for James has been developing staff to create a strong workforce; this includes varying the responsibilities for the herdsman and the dairying team, such as including foot trimming and fertility work.

It is motivational and it is also beneficial to the business, he says.

James is a former winner of the NFU Cymru/NFU Mutual Welsh Dairy Stockperson of the Year Award, a competition which recognises the important contribution a good dairy stockperson can make to a dairy enterprise, as well as the wider Welsh dairy industry.

For James, protocols are key to getting the best from the herd.

We have consistency in our day to day jobs, for instance we have a specific day of the week for a vet visit and another for drying off. We also have protocols for footbathing and generally keeping stock neat and tidy.

James farms with his father, Martin, and brother Josh. As well as the dairy herd, the business, known as the Martin Evans Group, also has a contracting business, a broiler unit and an agricultural construction company.

Martin, James and Josh have responsibility for different areas of the business but they work well as a team.

There is a little bit of something for everyone, we work well together but we all have our own areas of responsibility, says James.

See original here:
North Wales stockman's unusual route to the top - Wales Farmer

Read More...

Goops Netflix series: Its so much worse than I expected and I cant unsee it – Ars Technica

January 20th, 2020 5:46 am

Enlarge / This is the exact moment in the goop lab's third episode in which Gwyneth Paltrow admits she doesn't know the difference between a vagina and a vulva. She's making a hand gesture to say what she thought the "vagina" was.

Netflix

Disclaimer: This review contains detailed information about the Netflix series the goop lab with Gwyneth Paltrow. If you plan to watch the show (please, don't) and do not wish to know details in advance, this is not the review for you. Normally, we would refer to such information as "spoilers," but in our editorial opinion, nothing in this series is spoil-able.

In the third episode of Goop's Netflix series, a female guest remarks that we women are seen as "very dangerous when we're knowledgeable." [Ep. 3, 33:35]

"Tell me about it," Gwyneth Paltrow knowingly replies amid "mm-hmms"as if she has a first-hand understanding of this.

In fact, earlier in that same episode, we learn that the 47-year-old actor didn't even know what a vagina is.

"It's our favorite subjectvaginas!" Paltrow proclaims gleefully [Ep.3, 3:05]. Then the same guest, feminist sex educator Betty Dodson, corrects her: "The vagina is the birth canalonly. You want to talk about the vulva, which is the clitoris, and the inner lips, and all that good shit around it."

Paltrow giggles before responding, "The vagina is only the birth canal? Oh! See, I'm getting an anatomy lesson that I didn'tI thought that the vagina was the whole..."

"No, no, no, no," Dodson cuts her off.

To be fair, a lot of women might not be clear on this particular anatomical point. But for Paltrow, who claims to help empower women while touting dubious and dangerous products and treatments for said body partahem, vaginal steaming, cough, jade eggsyou'd hope she had a tight understanding of what a vagina isor isn't in this case.

But sadly, she didn't. And throughout the rest of the series, her ignorance and lack of critical thinking skills are on full display as a parade of questionable "experts" and ridiculous claims about health and science march across the small screen unchallenged.

(To be clear, Dodson was not among the dubious guests I'm referring to here; she is knowledgeable and respectable and was probably the most interesting and informative guest on the show.)

I'll go through each episode in more detail below, but for those who want to spare themselves from the bulk of the absurdity, I'll summarize here:

In so many ways, the goop lab with Gwyneth Paltrow is exactly what you'd expect based on what we already know about the Goop brand. The series provides a platform for junk science, gibberish, and unproven health claims from snake-oil-salesmen guests. It's a platform on which respected, trained medical experts are not considered the authorities on health and medical topics; where logic and critical thinking are enemies of open-mindedness; where anecdotes about undefined health improvements are considered evidence for specific medical treatment claims; where the subjective experiences of a few select individuals are equivalent to the results of randomized, controlled clinical trials; and where promoting unproven, potentially dangerous health claims is a means to empower women.

Paltrow and Loehnen sit in Goop's headquarters for an interview.

Netflix

Members of the "Goop gang" convene in Jamaica to convince themselves that magic mushrooms are a crucial part of a therapeutic journey.

Netflix

This woman isn't crying because she's on the goop lab. Instead, the tears are apparently coming on because she took a dose of psilocybin as part of a "therapy retreat" in Jamaica.

Netflix

A Gooper lies on the floor while tripping.

Netflix

These are often paired with anecdotes about participants in limited clinical trials. We hear their success stories without context about how the associated study at-large turned out or whether any positive results came with side effects or issues with bias.

Netflix

A Gooper gets a hug while tripping.

Netflix

Just another day in Jamaica, where Goopers gather to take shrooms, cry, and hug.

Netflix

The problem with this boilerplate statement is that most of the goop lab is full of one-sided, anecdotal claims that standard Western medical practice is all wrong. Right or wrong, that is most certainly a type of "medical advice," Gwyneth and co.

Netflix

But, beyond all of that, the show is just, well, boring.

Each episode uses the exact same structure. Each presents one of six health topics, which are (in order): psychedelics;"iceman" Wim Hof's breathing and cold-treatment method; female pleasure; anti-aging; energy healing; and psychics.

In each episode, you see Gwyneth Paltrow and Goop's chief content officer, Elise Loehnen, interview a couple of people involved in the episode's topic. The interviews take place in an airy, stylishly decorated office at Goop's Santa Monica headquarters. Interspersed between snippets of those interviews, you see groups of Goop-employee volunteers subject themselves to some therapy or experience related to the episode's topic. The interview dialogue from Goop headquarters is used to essentially narrate the Goopers' experiences. The Goopers' results are, in turn, intended to back up whatever claims the interviewees make.

It's a tiring structure for six straight episodes, and it's often not done well. The pacing is slow at times; some of the Goopers' experiences are just not engaging and seem like filler; some of their personal stories are introduced at the start of episodes and then inexplicably abandoned at the end; the interviews at Goop headquarters can seem drawn out and dry; and there are random tangents about Gwyneth Paltrow's life and the office environment at Goop headquarters.

Even if you're interested in the topics, getting through the episodes can feel like a slogand they're each only 30-35 minutes long.

It feels like the momentum of each episode is supposed to be driven by anticipation of how the Goopers' experiences match what the interviewees are saying. But we hardly ever get satisfying conclusions on that frontand we wouldn't be convinced even if we did. Instead, the show seems to move each episode along more by leaning on shock content that might best appeal to middle schoolersshowing glimpses of a woman having an orgasm, a Goop staffer getting a face lift using string that pulls her smile toward her ears, and a group of Goopers tripping on mushrooms.

Meanwhile, the goop lab makes no effort to question or critically evaluate any of its claims. There are no fact checks or counterpoints offered. There's no mention of any criticism and little to no warnings of potential harms.

In all, it's a show that you can safely skip. But, if you still want to know more about why the goop lab is so bad, let's run through the six episodes.

The first episode covers psychedelics and their potential to improve mental health. Paltrow and Loehnen sit down with Will Siu (a psychiatrist who supports "psychedelic Integration" in therapies) and Mark Haden (executive director of MAPS Canada, which is an affiliate of the Multidisciplinary Association for Psychedelic Studies, a nonprofit created in 1985 to advocate for the medical benefits and use of psychedelic drugs, such as MDMA and LSD). Siu received training at MAPS.

Being the person that people perceive me to be is inherentlytraumatic.

For instance, in 2016 the Food and Drug Administration greenlighted the first Phase III trial to assess whether or 3,4-Methylenedioxymethamphetamine (MDMA)known as "molly" or "ecstasy"can improve the symptoms of PTSD. And treatments with psilocybin, the psychedelic component of "magic" mushrooms, has yielded positive results in small trials on people struggling with depression.

While that research is legitimate and interesting, the Goop episode approached the topic in the dumbest possible way: a group of four Goop employees hop on a plane to Jamaica to trip on mushrooms. Two of the Goopers weren't trying to address mental health. One Gooper said she wanted to feel more creative and like her "authentic self," and Loehnen, who went, said she wanted a "psychospiritual experience." The other two were trying to "process some personal trauma."

While the clinical trials are evaluating specific drug doses to treat well-defined symptoms in tightly controlled, weeks-long programs, the Goopers drank mushroom tea once, in a "more ceremonial setting," surrounded by what they described as "psychedelic elders."

Meanwhile, the interview back at Goop headquarters starts rambling, with discussion around vague mental health issues, the value of "connecting people," harmful societal norms, and how basically everyone is suffering. Paltrow notes at one point that she, too, suffers mental-health problems despite her wealth and status, and she adds that "being the person that people perceive me to be is inherently traumatic." [Ep.1, 29:00] Poor Gwyneth.

At the end of the episode, some of the Goopers talk about how the experience was intensewell, yeah. We don't hear back from the woman who wanted to be more creative, so we can only hope things worked out for her. But one of the Goopers processing trauma (in his case, trauma of having an emotionally distant father) said in a final one-on-one discussion with Paltrow that he felt more of an "openness" after the experience. He thanked Paltrow for letting him go.

Yeah, OK.

NEXT.

Read more:
Goops Netflix series: Its so much worse than I expected and I cant unsee it - Ars Technica

Read More...

Chip Walter is dying for you to read his new book on immortality. Or is he? – NEXTpittsburgh

January 20th, 2020 5:46 am

Is it possible to cure aging?

Chip Walter says yes. The author spent years researching and writing his new book Immortality, Inc.: Renegade Science, Silicon Valley Billions, and the Quest to Live Forever which explores the efforts being taken to cure aging and hence dramatically prolong life.

This is not a work of fiction.

Walter, a science journalist, filmmaker, skeptic and former CNN bureau chief interviewed many authorities, including Craig Venter, the scientist who accelerated the completion of the first human genome and Robert Hariri, one of the worlds leading stem cell experts.

The book, published by National Geographic, is available in bookstores and online. As part of his tour to promote the book, Walter will appear at the Carnegie Library Lecture Hall in Oakland on Thursday, Jan. 16 to discuss the death of growing old. The event, which is part of the Pittsburgh Arts & Lecture Series, is free with registration.

The topic is fascinating with so many implications. NEXTpittsburgh caught up with Walter to ask him some burning questions of our own.

Define immortality. Is it infinite or are we talking hundreds of years?

None of us is going to live forever. Sooner or later well be hit by a bus or lightning, or maybe an angry spouse who just cant stomach celebrating their 400th anniversary! We used the title Immortality, Inc. in the book to differentiate it from simply living a couple of extra years or even a couple of extra decades. So, this book doesnt pretend to have revealed science that will guarantee infinite life, but it does explore scientific advances on the horizon that will very likely diminish and then eliminate aging. And since aging and age-related diseases are the number one reason why we die (one million people a week die of age-related disease), curing aging would radically lengthen healthy life spans into the hundreds of years, crazy as that may sound.

Do we have to cure cancer and conditions like depression first?

The opposite, I think.

If scientists solve aging, then it would also vastly reduce the number of people who die from cancer and many other diseases. The reason most people get cancer is because they are aging. If science can solve the underlying, biological causes of aging, these killer diseases would largely disappear. Well basically grow younger. And, as a rule, most people do not die when they are young unless its from an accident, murder or a severe genetic problem.

So, by curing aging, we will, in one fell swoop, cure much of the cancer, heart disease, Alzheimers and other major diseases. This arguably makes solving aging the best way to eliminate a whole group of diseases, rather than try to track each one down individually like were playing some game of whack-a-mole. In fact, you could argue that these diseases will never be eliminated unless aging is eliminated first. Well just create a series of band-aids, but eventually something will get us.

Issues like depression are more problematic because they are not directly related to aging (though they sometimes can be). But, an additional bonus is that as science attempts to cure aging, we may well develop cures for many diseases that afflict people in their youth genetic diseases, mental and emotional syndromes, viruses, childhood cancer because we will understand the genomics of the human body so much better.

How close are we really to achieving immortality and what will be the first discovery?

I doubt there will be a silver bullet any more than scientists found a silver bullet that would cure cancer when the war against cancer was launched in the 1970s. Its just too complex. But, I do believe that some major advances will be revealed and in use within the next four years. These advances will be incremental, but they will also gather speed. First, I expect to see a far broader use of stem cell technology to repair damaged and diseased bodies from arthritis to kidney disease. A company and scientist I explore in the book (Celularity) is tackling that.

Next, will come major advances as we better understand the human genome. We are gathering more and more information that is enabling us to decode the genome so that we can understand and develop drugs tailored to each individual. But first we have to understand what interactions within our DNA unravel the human body in the first place. ( I explore a company called Human Longevity, founded by genomic pioneer Craig Venter, that is working on that.) Third, based largely on genomics, will come advances that truly unveil why we age at all. Clearly we do. But why? Calico and Apple Chairman Arthur Levinson is working on that.

How will we solve all of these complex problems? Only the development of increasingly robust computing can solve that problem, and that software is advancing at an exponential pace. Ultimately, those machines, working with scientists of many stripes will crack some of these profoundly complex challenges. Generally, I believe those are the four forces that I believe will lead to the end of aging.

Has there been an actual breakthrough and if so, what is it?

There have been breakthroughs, but no cures (because, again, I doubt there will be a silver bullet). But as I reveal in the book, scientists now know, definitively, that genetics is the source behind why we age (or one of the key sources). We also know that certain key genes in other animals (like mice) can be switched, and when they are, the mice live far longer and healthier lives, sometimes more than four times longer. We also know that some mammals simply dont age. They die of other things, but not aging. This was discovered while I was writing the book. Scientists in the book also have discovered what they suspect is the explanation of youth. Why are we born young? How does that happen and then why and how do we age? So, we have already seen significant fundamental advances, and theyll continue to come.

How much of the book is about the personalities and how much is about science?

I did not want to write a book that was just a bland science survey filled with a bunch of facts. Theres a difference between fact and truth. When I first set out to explore and research Immortality, Inc., the main question in my mind was this: are we actually now living in a time when science could solve one of the greatest mysteries the human race has ever faced? And if science can accomplish that, what does it mean? To tell that story I needed to understand the history of the key scientists, and the finances and thinking of those involved. And I needed to gain access to them. It wasnt easy, but eventually I did. Much of what I found is exclusive information. Unknown until now.

In the end I wanted to thread all of those themes together into one larger, compelling story. How did something like this come to be? Who were these scientists? What motivated them? Are they crazy or geniuses? So, I spent a lot of time with all of them and I wrote about who they are and what led them to undertake such a monumental task. Who does that? Once I set the stage for outlining the personalities and the cultural and historical and financial issues, then I dove into the science that these scientists and companies were developing. I think this makes the book a much more compelling human story. At least I hope so.

How would you respond to critics who think the book is more about very wealthy older people in a quest to cheat death?

Well, the simple answer is thats not what the book is about. So folks should read it and theyll see that such an assumption would be off-base. I am sure that there are many well-heeled older people who would like to live longer and healthier lives. And I am sure that there are many not-so-well-heeled people who would as well. That doesnt make them evil. This is only evil if the rich, and only the rich, hold on to technologies that would lead to longer life. That would be wrong. But history shows that as new technologies evolve, costs drop and then they become more ubiquitous. I believe that will happen here. Insurance companies will begin to see that they can save a lot more money by enabling people to remain healthy longer than by paying to have them go into the hospital again and again.

When it comes right down to it, does anyone want to die (unless you are facing horrible physical, emotional or mental pain)? I mean when each of us is facing death, that day, do we really want to blink out? Living is literally wound into our DNA. Every living thing does everything it can to remain alive, until it simply cant anymore. From the beginning of time we have always tried to avoid dying. Thats the origin and purpose of Medicine with a capital M. Now, if we solve that problem and huge numbers of us live exceptionally long, will that create problems? Absolutely. But again, will most people say, Its okay, Ill die so we dont have an over population problem. Lets imagine someone has cancer and science offers a potential solution, do they say, No thanks. Not usually. I suspect the same will be true of drugs and treatments that extend life. A bigger issue in my mind is how, as a society, we are going to deal with a world in which we are living, not decades longer (as we already are), but hundreds of years longer. These advances are going to capsize everything. So I suggest we get a handle on it now.

Did you discuss immortality with any religious leaders or people in the death care industry? What were their thoughts?

I did speak to those people, but I didnt get deeply into it in the book or it would have been 600 pages long. Peoples feelings about this are all over the map, pro and con. There is, however, no religion that fundamentally holds that we must die. Some people, however, do feel its wrong to want to cheat death. That somehow its unnatural or that God wants us to die. But if this were universally true, then why take antibiotics? Why try to save people from automobile accidents? Why try to cure or treat any disease? All of these are basically ways to cheat death, at least for awhile.

But again, I want to clarify that my goal with this book isnt to advocate one way or another for outfoxing the grim reaper. I am simply trying to tell the story of these forces and people who are creating profound and fundamental change in the human story. I wanted to tell that tale, not explore the theology and philosophy of life and death because its not about my point of view. Its about whats happening and why its important.

Carnegie Library Lecture HallChip WalterImmortalityInc.National GeographicPittsburgh Arts and Lecture Series

More here:
Chip Walter is dying for you to read his new book on immortality. Or is he? - NEXTpittsburgh

Read More...

Page 749«..1020..748749750751..760770..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick